var title_f17_62_18400="Spitz nevus face";
var content_f17_62_18400=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Spitz nevus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 377px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_62_18400=[""].join("\n");
var outline_f17_62_18400=null;
var title_f17_62_18401="Ornidazole: International drug information";
var content_f17_62_18401=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ornidazole: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Avrazor (CZ);",
"     </li>",
"     <li>",
"      Danubial (MX);",
"     </li>",
"     <li>",
"      Mebaxol (AR);",
"     </li>",
"     <li>",
"      Ornidazol Richet (AR);",
"     </li>",
"     <li>",
"      Ornidazole Cooper (FR);",
"     </li>",
"     <li>",
"      Tiberal (AR, BE, CH, CZ, FR, IT, LU, MX);",
"     </li>",
"     <li>",
"      Tinerol (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiprotozoal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of parasitic infections, including amebiasis, giardiasis, and",
"     <i>",
"      Trichomonas vaginalis",
"     </i>",
"     ; treatment of infections due to susceptible strains of anaerobic bacteria",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Children &gt;35 kg and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Trichomonas:",
"     </i>",
"     1.5 g single dose for one day; alternatively, 0.5 g twice daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amebiasis (with amebic dysentery): 1.5 g as a single dose for 3 days; patients &gt;60 kg should take 1 g twice daily for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Giardiasis: 1.5 g as a single dose for 1-2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anaerobic bacterial infection: Initially infusion of 0.5-1 g followed by 0.5 g every 12 hours for 5-10 days; oral therapy substituted at the earliest opportunity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Amebic liver abscess and severe amebic dysentery: 0.5-1 g, followed by 0.5 g every 12 hours for 3-6 days",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Infusion: 500 mg/100 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Tablet: 250 mg, 500 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10423 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-4F5D24ED7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_62_18401=[""].join("\n");
var outline_f17_62_18401=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303417\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979820\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979823\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979819\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821199\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979822\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10423\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10423|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_62_18402="Patient information: Breech pregnancy (The Basics)";
var content_f17_62_18402=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/87296\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/20/7495\">",
"         Pregnancy terms",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/45/18131\">",
"          Different baby positions in the uterus",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/40/18051\">",
"           Vaginal delivery (childbirth)",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/57/23440\">",
"            Cesarean delivery for a breech pregnancy",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?16/21/16723\">",
"         Patient information: C-section (cesarean delivery) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/45/38609\">",
"         Patient information: Developmental dysplasia of the hip (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/44/1732\">",
"         Patient information: Having twins (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/13/12499\">",
"         Patient information: Labor and delivery (childbirth) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/29/37331\">",
"         Patient information: Prenatal care (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/45/11988\">",
"         Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Breech pregnancy (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H581001981\">",
"      <span class=\"h1\">",
"       What is a breech pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The word &ldquo;breech&rdquo; describes the position of a baby in the mother&rsquo;s uterus (womb) (",
"      <a class=\"graphic graphic_figure graphicRef82935 \" href=\"UTD.htm?7/20/7495\">",
"       figure 1",
"      </a>",
"      ). Before birth, babies lie in the uterus in different positions. They can lie with their head, shoulders, legs, or buttocks closest to the vagina. Doctors call it &ldquo;breech&rdquo; when a baby&rsquo;s feet or buttocks are closest to the vagina (",
"      <a class=\"graphic graphic_figure graphicRef72643 \" href=\"UTD.htm?17/45/18131\">",
"       figure 2",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Early in pregnancy, it is common for babies to be in a breech position. But toward the end of pregnancy, most babies lie with their head closest to the vagina. The head-down position is the safest position for a baby to be in for a vaginal delivery (",
"      <a class=\"graphic graphic_figure graphicRef59831 \" href=\"UTD.htm?17/40/18051\">",
"       figure 3",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      A breech pregnancy is when a baby is lying in the breech position toward the end of pregnancy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H581002145\">",
"      <span class=\"h1\">",
"       What causes a breech pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most breech pregnancies happen by chance.",
"     </p>",
"     <p>",
"      But some breech pregnancies happen because of a problem with the baby, the mother&rsquo;s uterus or placenta, or the amount of amniotic fluid around the baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H581002160\">",
"      <span class=\"h1\">",
"       Does a breech pregnancy cause symptoms?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sometimes. Women might feel discomfort under their rib cage, where the baby&rsquo;s head presses. Women can also feel their baby kicking in their lower belly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H581002175\">",
"      <span class=\"h1\">",
"       How will my doctor or midwife know if I have a breech pregnancy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;He or she will do an exam to check your baby&rsquo;s position. This involves pressing on your belly to feel the position of your baby&rsquo;s head. In the last 3 months of pregnancy, your doctor, nurse, or midwife will check your baby&rsquo;s position at each visit.",
"     </p>",
"     <p>",
"      You might also have a test called an ultrasound to check your baby&rsquo;s position. An ultrasound uses sound waves to create pictures of your baby in your uterus.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H581002190\">",
"      <span class=\"h1\">",
"       What happens if my baby is breech?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most breech babies turn head down (by themselves) before labor.",
"     </p>",
"     <p>",
"      If your baby is still in a breech position near your due date, your doctor or midwife might recommend trying to turn your baby around to a head-down position. To do this, your doctor or midwife will press on your belly and try to move your baby. If this works, and your baby moves to a head-down position, you can go into labor and try to have a vaginal delivery. If it doesn&rsquo;t work and your baby stays in the breech position, your doctor or midwife will likely recommend that you have a c-section (surgery) to deliver your baby (",
"      <a class=\"graphic graphic_figure graphicRef87130 \" href=\"UTD.htm?22/57/23440\">",
"       figure 4",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      In some cases, babies who are breech are delivered vaginally. This is called a vaginal breech delivery. But during this type of delivery, problems involving the baby or mother are more likely to happen. Because of this, vaginal breech deliveries are not usually done.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H581002222\">",
"      <span class=\"h1\">",
"       What if I am having twins?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are having twins, your doctor or midwife will check the position of each twin. If the first twin is in a breech position, your doctor or midwife will probably recommend that you have a c-section to deliver your babies. If the first twin is head down and the second twin is breech, your doctor or midwife will discuss your choices with you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H581002112\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/13/12499?source=see_link\">",
"       Patient information: Labor and delivery (childbirth) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/44/1732?source=see_link\">",
"       Patient information: Having twins (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/29/37331?source=see_link\">",
"       Patient information: Prenatal care (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/21/16723?source=see_link\">",
"       Patient information: C-section (cesarean delivery) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/45/38609?source=see_link\">",
"       Patient information: Developmental dysplasia of the hip (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=see_link\">",
"       Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?17/62/18402?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87296 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-37B631BF3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_62_18402=[""].join("\n");
var outline_f17_62_18402=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H581001981\">",
"      What is a breech pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H581002145\">",
"      What causes a breech pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H581002160\">",
"      Does a breech pregnancy cause symptoms?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H581002175\">",
"      How will my doctor or midwife know if I have a breech pregnancy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H581002190\">",
"      What happens if my baby is breech?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H581002222\">",
"      What if I am having twins?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H581002112\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/87296\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/20/7495\">",
"      Pregnancy terms",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/45/18131\">",
"       Different baby positions in the uterus",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/40/18051\">",
"        Vaginal delivery (childbirth)",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/57/23440\">",
"         Cesarean delivery for a breech pregnancy",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/45/11988?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/21/16723?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/45/38609?source=related_link\">",
"      Patient information: Developmental dysplasia of the hip (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/44/1732?source=related_link\">",
"      Patient information: Having twins (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/13/12499?source=related_link\">",
"      Patient information: Labor and delivery (childbirth) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/29/37331?source=related_link\">",
"      Patient information: Prenatal care (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_62_18403="Ascariasis - computed tomography";
var content_f17_62_18403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Ascariasis - computed tomography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 392px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnified views of orally-contrasted axial CT of the abdomen.",
"    <br>",
"     (A) Longitudinal views of ascaris lumbricoides within the jejunal lumen. Note the lack of contrast in the gut of the worm.",
"     <br>",
"      (B) Axial views of ascarids, again without contrast in worm gut.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Pylant A, Hinshaw JW, Leonard RB, et al. Intestinal Ascariasis: CT findings and diagnosis. South Med J 2006; 99:317. Copyright &copy; 2006 Lippincott Williams &amp; Williams.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_62_18403=[""].join("\n");
var outline_f17_62_18403=null;
var title_f17_62_18404="Meclizine: Pediatric drug information";
var content_f17_62_18404=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Meclizine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37141?source=see_link\">",
"    see \"Meclizine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/33/13844?source=see_link\">",
"    see \"Meclizine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F191757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Antivert&reg;;",
"     </li>",
"     <li>",
"      Bonine&reg; [OTC] [DSC];",
"     </li>",
"     <li>",
"      Dramamine&reg; Less Drowsy Formula [OTC];",
"     </li>",
"     <li>",
"      Medi-Meclizine [OTC];",
"     </li>",
"     <li>",
"      Trav-L-Tabs&reg; [OTC];",
"     </li>",
"     <li>",
"      VertiCalm&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiemetic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihistamine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37141?source=see_link\">",
"      see \"Meclizine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;12 years and Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Motion sickness: 25-50 mg 1 hour before travel, repeat dose every 24 hours if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vertigo: 25-100 mg/day in divided doses",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F191739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral, as hydrochloride: 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 12.5 mg, 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Antivert&reg;: 12.5 mg, 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Antivert&reg;: 50 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dramamine&reg; Less Drowsy Formula: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Medi-Meclizine: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trav-L-Tabs&reg;: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VertiCalm&trade;: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral, as hydrochloride: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bonine&reg;: 25 mg [DSC] [scored; raspberry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F191726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with food to decrease GI distress",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of motion sickness; management of vertigo",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F191779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Antivert&reg; may be confused with Anzemet&reg;, Axert&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - varies based on comorbidity; Strength of recommendation - varies based on comorbidity)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F191777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Drowsiness, fatigue, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to meclizine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1060047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with angle-closure glaucoma or obstructive diseases of the GI or GU tract",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F191735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F191736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F191747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies; however, an increased risk of fetal abnormalities has not been observed following maternal use of meclizine during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Has central anticholinergic action and CNS depressant activity; decreases excitability of the middle ear labyrinth and blocks conduction in the middle ear vestibular-cerebellar pathways",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1060059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Oral: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 12-24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1060060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: As metabolites in urine and as unchanged drug in feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1060052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/33/13844?source=see_link\">",
"      see \"Meclizine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; avoid alcohol",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12575 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-FE77A46CF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_62_18404=[""].join("\n");
var outline_f17_62_18404=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191757\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060053\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060048\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191739\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191726\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060057\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060056\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191779\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191777\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060061\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060047\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299654\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191735\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191736\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191747\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060046\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060059\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060060\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060052\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12575\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12575|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37141?source=related_link\">",
"      Meclizine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/33/13844?source=related_link\">",
"      Meclizine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_62_18405="Triprolidine, pseudoephedrine, and codeine: Patient drug information";
var content_f17_62_18405=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Triprolidine, pseudoephedrine, and codeine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/36/24134?source=see_link\">",
"     see \"Triprolidine, pseudoephedrine, and codeine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F231846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CoActifed&reg;;",
"     </li>",
"     <li>",
"      Covan&reg;;",
"     </li>",
"     <li>",
"      ratio-Cotridin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop coughing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703090",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to triprolidine, pseudoephedrine, codeine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Head injury, raised pressure in the brain, bowel block, lung disease, or seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not for coughs due to smoking or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (syrup) if you cannot swallow pills.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12144 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6D34BE7A96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_62_18405=[""].join("\n");
var outline_f17_62_18405=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231846\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021656\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021658\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021657\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021662\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021663\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021665\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021660\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021661\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021666\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021667\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/36/24134?source=related_link\">",
"      Triprolidine, pseudoephedrine, and codeine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_62_18406="Gastric artery aneurysm associated with pancreatitis";
var content_f17_62_18406=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F53264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F53264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Gastric artery aneurysm associated with pancreatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 408px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is a round collection of iodinated contrast within the area of inflammatory change consistent with a gastric artery aneurysm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of J Pierre Sasson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_62_18406=[""].join("\n");
var outline_f17_62_18406=null;
var title_f17_62_18407="Naproxen and pseudoephedrine: Drug information";
var content_f17_62_18407=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Naproxen and pseudoephedrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/17/10517?source=see_link\">",
"    see \"Naproxen and pseudoephedrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3033586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aleve&reg;-D Sinus &amp; Cold [OTC];",
"     </li>",
"     <li>",
"      Aleve&reg;-D Sinus &amp; Headache [OTC];",
"     </li>",
"     <li>",
"      Sudafed&reg; 12 Hour Pressure + Pain [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3033590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Decongestant/Analgesic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3033615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cold, sinus, and flu symptoms:",
"     </b>",
"     Oral: One caplet every 12 hours (maximum dose: 2 caplets/24 hours); treatment for &gt;7 days is not recommended unless directed by healthcare provider.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F3033614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cold, sinus, and flu symptoms:",
"     </b>",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3033616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3033621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, extended release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aleve&reg;-D Sinus &amp; Cold, Aleve&reg;-D Sinus &amp; Headache, Sudafed&reg; 12 Hour Pressure + Pain: Naproxen sodium 220 mg [equivalent to naproxen 200 mg and sodium 20 mg] and pseudoephedrine hydrochloride 120 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3033588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3033618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not crush or chew; swallow whole. Drink a full glass of water with each dose. May administer with food or milk if upset stomach occurs.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3033591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of cold, sinus, and flu symptoms (including nasal congestion, sinus congestion/pressure, headache, minor body aches and pains, and fever)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3033600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3033595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pseudoephedrine, naproxen, aspirin, other NSAIDs, or any component of the formulation; during or within 14 days of MAO inhibitor therapy; immediately prior to or after coronary artery bypass graft (CABG) surgery",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3033596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aseptic meningitis: May increase the risk of aseptic meningitis, especially in patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding/hemostasis: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events: NSAIDs are associated with an increased risk of adverse cardiovascular events, including MI, stroke, and new-onset or worsening of pre-existing hypertension. Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention. Avoid use in heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation. These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery: Use is contraindicated immediately prior to or after coronary artery bypass graft (CABG) surgery. Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with decreased hepatic function. Closely monitor patients with any abnormal LFT. Severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or angle-closure glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or urinary obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Not recommended for use in patients with advanced renal disease. Long-term NSAID use may result in renal papillary necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Use with caution in patients with thyroid disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: The elderly are at increased risk for adverse effects (especially peptic ulceration, CNS effects, renal toxicity) from NSAIDs even at low doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for self-medication (OTC use) in children &lt;12 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): Prior to self-medication, patients should contact healthcare provider if they have had recurring heartburn, stomach pain or upset, ulcers, bleeding problems, asthma, high blood pressure, heart or kidney disease, thyroid disease, diabetes, glaucoma, enlarged prostate, other serious medical problems, are currently taking a diuretic, aspirin, anticoagulant, other NSAIDs, or are &ge;60 years of age. Recommended dosages and duration should not be exceeded, due to an increased risk of GI bleeding, MI and stroke. Patients should stop use and consult a healthcare provider if symptoms get worse, newly appear, or continue; if an allergic reaction occurs; if feeling faint, vomit blood or have bloody/black stools; if nervousness, dizziness, or sleeplessness occurs; if having difficulty swallowing or heartburn, or if fever lasts for &gt;3 days or congestion lasts for &gt;7 days. Consuming &ge;3 alcoholic beverages/day or taking longer than recommended may increase the risk of GI bleeding.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F3033606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3033605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F6759058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Naproxen absorption rate/levels may be decreased if taken with food. Onset of effect may be delayed if pseudoephedrine is taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical:",
"     <i>",
"      Naproxen:",
"     </i>",
"     Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American, Panax, Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, white willow (all have additional antiplatelet activity).",
"     <i>",
"      Pseudoephedrine:",
"     </i>",
"     Avoid ephedra, yohimbe (may cause hypertension).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3033592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3033594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F3033617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drink a full glass of water with each dose. May take with food or milk if upset stomach occurs.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Aleve-D Sinus &amp; Headache Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120-220 mg (10): $4.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Sudafed Pressure+Pain 12 HR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120-220 mg (16): $8.40",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3033609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Naproxen: Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which result in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pseudoephedrine: Directly stimulates alpha-adrenergic receptors of respiratory mucosa causing vasoconstriction; directly stimulates beta-adrenergic receptors causing bronchial relaxation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3033611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/62/18407/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10315 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-6FA69E1D15-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_62_18407=[""].join("\n");
var outline_f17_62_18407=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033586\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033590\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033615\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033614\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033616\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033621\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033588\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033618\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033591\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033600\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033595\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033596\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033606\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033605\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6759058\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033592\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033594\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033617\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322948\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033609\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3033611\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10315\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10315|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/17/10517?source=related_link\">",
"      Naproxen and pseudoephedrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_62_18408="Child neglect and emotional abuse";
var content_f17_62_18408=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Child neglect and emotional abuse",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/62/18408/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/62/18408/contributors\">",
"     Erin E Endom, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/62/18408/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/62/18408/contributors\">",
"     Daniel M Lindberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/62/18408/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/62/18408/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/62/18408/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/62/18408/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Child maltreatment is intentional harm or threat of harm to a child by a person who is acting in the role of caretaker [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/1\">",
"     1",
"    </a>",
"    ]. Four categories of child maltreatment are commonly described: physical abuse, sexual abuse, emotional abuse, and child neglect. Child neglect and emotional abuse will be reviewed here. Physical abuse and sexual abuse are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHILD NEGLECT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Child neglect is the most prevalent form of child abuse, accounting for more than one-half of cases reported to child protection services [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Child neglect is defined by the National Center of Child Abuse and Neglect as failure to provide for a child's basic physical, emotional, educational, or medical needs [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. Specific types of neglect are defined as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Physical neglect",
"      </strong>",
"      &ndash; Failure to provide adequate food, clothing, shelter, hygiene, protection; inadequate supervision with risk of harm to the child.",
"     </li>",
"     <li>",
"      <strong>",
"       Emotional neglect",
"      </strong>",
"      &ndash; Failure to provide love, affection, security, and emotional support; failure to provide psychological care when needed; spouse abuse in presence of the child. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31097?source=see_link\">",
"       \"Childhood exposure to intimate partner violence\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Educational neglect",
"      </strong>",
"      &ndash; Failure to enroll the child in school or ensure school attendance or home schooling; failure to address specific educational needs.",
"     </li>",
"     <li>",
"      <strong>",
"       Medical neglect",
"      </strong>",
"      &ndash; Refusal to seek or delay in seeking medical care resulting in damage or risk of damage to the child's health.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Child neglect encompasses both actual and potential harm (eg, failure to use a child safety seat, even if the child is not injured) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/4\">",
"     4",
"    </a>",
"    ]. The harm may be physical or psychological and may occur in the short- or long-term. Child neglect can be attributed to factors related to the child (eg, does not tell the parent about an injury), parent (eg, depression), family (eg, social isolation, religious beliefs), or community (eg, poor access to services) (",
"    <a class=\"graphic graphic_algorithm graphicRef53333 \" href=\"UTD.htm?18/43/19135\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/4,7\">",
"     4,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authors define child neglect as the \"neglectful failure to supply the needs of the child\" [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, neglect is a nondeliberate act and distinguished from the deliberate or malicious failure to supply the needs of the child, which they call \"deprivational abuse\" [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Child neglect accounts for more than 50 percent of cases reported to child protection services in developed countries (eg, UK, US, Canada, Australia) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In 1993 it was estimated that 3 percent of the children in the United States were neglected [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/3\">",
"     3",
"    </a>",
"    ]. Each year in the United States, child maltreatment accounts for approximately 2000 childhood deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/11\">",
"     11",
"    </a>",
"    ]. At least one-third of these are a consequence of neglect (eg, abandonment, starvation, medical neglect, inadequate supervision) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for child neglect are related to a disorganized family system and include parental substance abuse, unemployment, physical disability, or cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/12,13,15-18\">",
"     12,13,15-18",
"    </a>",
"    ]. Difficult child temperament was related to emotional neglect in one study of 121 urban, low-income families with a child younger than 30 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/19\">",
"     19",
"    </a>",
"    ]. An inverse relationship between child neglect and years of maternal education has been described among low-income women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/6\">",
"     6",
"    </a>",
"    ]. Poverty, violence, absence of support from social networks, and homelessness also may contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/6,12,20-22\">",
"     6,12,20-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The manifestations of child neglect are protean and can include any or all of the following: nonorganic failure to thrive; developmental delay [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/6\">",
"     6",
"    </a>",
"    ]; starvation or dehydration; poor hygiene of child's body, clothes, or diapers; severe, untreated dental caries [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]; school truancy; injuries caused by lack of supervision (ingestions, burns, bathtub near-drownings, or other \"accidental\" injuries); and physical abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/6,25,26\">",
"     6,25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/12/14538?source=see_link&amp;anchor=H11#H11\">",
"     \"Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Few studies have examined the consequences of child neglect and those that have are limited by their size, failure to separate neglect from physical abuse, or failure to control for potential confounding variables (eg, maternal education, depression, poverty) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/27\">",
"     27",
"    </a>",
"    ]. Nonetheless, the following effects of child neglect have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/4,27-31\">",
"     4,27-31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dysfunctional personal relationships",
"     </li>",
"     <li>",
"      Speech and language disorders",
"     </li>",
"     <li>",
"      Learning difficulties",
"     </li>",
"     <li>",
"      Emotional and behavior problems",
"     </li>",
"     <li>",
"      Delinquent and criminal behavior (eg, substance abuse)",
"     </li>",
"     <li>",
"      Health problems (eg, failure to thrive)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Child neglect can be attributed to factors related to the child, parent, family, or community [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/4\">",
"     4",
"    </a>",
"    ]. The cultural context and setting in which the child's needs are inadequately met must be considered in the evaluation of child neglect [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/4\">",
"     4",
"    </a>",
"    ]. The evaluation should seek to answer the following questions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Are the child's needs being inadequately met?",
"     </li>",
"     <li>",
"      Is there evidence of actual or potential harm?",
"     </li>",
"     <li>",
"      Is there a pattern of neglect?",
"     </li>",
"     <li>",
"      Has child protective services been involved?",
"     </li>",
"     <li>",
"      What factors are contributing to the neglect? (Is the parent aware of the problem? Does poverty play a role? Is there access to necessary services?) (",
"      <a class=\"graphic graphic_algorithm graphicRef53333 \" href=\"UTD.htm?18/43/19135\">",
"       algorithm 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      What family strengths or resources are available?",
"     </li>",
"     <li>",
"      What interventions have been tried in the past? What were the results?",
"     </li>",
"     <li>",
"      Is the family motivated to make necessary changes?",
"     </li>",
"     <li>",
"      Are the necessary resources available?",
"     </li>",
"     <li>",
"      How much help is the family willing to accept on behalf of their child?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Physical neglect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examples of physical neglect include inadequate provision of food, shelter, or clothing; inadequate hygiene; inadequate protection from environmental hazards; and inadequate supervision [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inadequate provision of food may result from poverty or inappropriate dietary selection (eg, from following fad diets) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/32\">",
"     32",
"    </a>",
"    ]. Thus, the assessment of poor weight gain or failure to thrive should include a history of dietary intake and feeding behavior, evaluation of the family's resources (eg, are they eligible for or receiving a supplemental nutrition program?), and consideration of other diagnostic possibilities (",
"    <a class=\"graphic graphic_table graphicRef56603 \" href=\"UTD.htm?42/14/43245\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/12/14538?source=see_link&amp;anchor=H14#H14\">",
"     \"Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inadequate hygiene, clothing, or protection from environmental hazards (eg, access to loaded guns, or lack of use of car seats or smoke alarms) may be due to a lack of financial resources and a sign that parents are unable to meet other important needs for their children (eg, nutrition or housing). Evaluation of these forms of physical neglect should include assessment of the family's resources and knowledge regarding injury prevention. Questions regarding these sensitive issues can be introduced with a statement like: \"I am interested in helping every child to be in a safe environment. There are some problems lots of families have, so I'm asking everyone these questions&hellip;\" [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evaluation of supervision that is inadequate for the child's developmental needs should include asking parents about their options for child care; whether they ever leave the child alone; whether there is an another adult available (eg, by phone) when the child is left alone; and whether the neighborhood is safe [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Emotional neglect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emotional neglect may occur in the setting of parental depression or domestic abuse. In assessing emotional neglect, the provider should ask about parent-child interactions and the ways in which the parent expresses his or her feelings for the child (",
"    <a class=\"graphic graphic_table graphicRef63391 \" href=\"UTD.htm?10/52/11083\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Educational neglect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Educational neglect involves failure to provide adequate developmental or intellectual stimulation; to enroll the child in school; to ensure school attendance; or to provide home schooling [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/4,32\">",
"     4,32",
"    </a>",
"    ]. Evaluation of educational neglect involves determining why the child is not attending school and may require talking to teachers, principals, or school nurses to clarify the situation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Medical neglect",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to refusal to seek or delay in seeking medical care, medical neglect also includes lack of adherence to health care recommendations. Lack of adherence can be due to lack of education, motivation, resources, or understanding [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/4,32\">",
"     4,32",
"    </a>",
"    ]. When medical neglect is being considered, the following questions are important [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is the recommended treatment necessary and likely to have a significant benefit compared with alternative treatments being used (or no treatment)?",
"     </li>",
"     <li>",
"      Is the child harmed or at risk of harm because of lack of care?",
"     </li>",
"     <li>",
"      What are the possible barriers to care (eg, transportation)?",
"     </li>",
"     <li>",
"      Are there cultural or religious factors that are contributing to lack of care or adherence to the treatment plan?",
"     </li>",
"     <li>",
"      If medical treatment was delayed, would a reasonable layperson have recognized the need for medical treatment?",
"     </li>",
"     <li>",
"      Was the treatment plan clear? Were the recommendations in writing? Was the plan agreed upon?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of child neglect requires that the healthcare provider convey to the family his or her concerns about the child's well-being and safety. The factors contributing to child neglect should be identified, prioritized, and addressed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/4,35\">",
"     4,35",
"    </a>",
"    ]. The management can be enhanced by working with an interdisciplinary team [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific objectives with measurable outcomes should be established and the family should be engaged in development of the treatment plan. Access to community services and resources should be provided. Involvement of a mental health specialist, social worker, nutritionist,",
"    <span class=\"nowrap\">",
"     behavior/development",
"    </span>",
"    specialist, education specialist, or visiting nurse may be necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/4\">",
"     4",
"    </a>",
"    ]. Parents may need help in making suitable child care arrangements or in finding ways to express their love to their child. These interventions may be facilitated through the involvement of Child Protective Services (CPS). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Mandated reporting'",
"    </a>",
"    below.) Data regarding the success of these interventions are not available.",
"   </p>",
"   <p>",
"    The National Clearinghouse on Child Abuse and Neglect provides additional information and resources regarding prevention, management, and statutes regarding reporting of child abuse and neglect (",
"    <a class=\"external\" href=\"file://www.childwelfare.gov/\">",
"     www.childwelfare.gov",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef57326 graphicRef69110 \" href=\"UTD.htm?12/7/12414\">",
"     table 3A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for hospitalization in the neglected child is dependent upon several factors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/2,36\">",
"     2,36",
"    </a>",
"    ]. Hospitalization may be warranted for the treatment of certain conditions (eg, ingestion, near-drowning). In addition, hospitalization may be indicated for the safety of the child [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/2,36\">",
"     2,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the parent is unable to assume responsibility for the child (eg, due to being overwhelmed, depressed, withdrawn) and safe, temporary placements are otherwise unavailable.",
"     </li>",
"     <li>",
"      If the response of child protective services or other community agency will be unacceptably delayed.",
"     </li>",
"     <li>",
"      If chronic neglect has been a problem.",
"     </li>",
"     <li>",
"      To provide a protective environment where the child can be evaluated by knowledgeable consultants (if such specialized services are not available in the community).",
"     </li>",
"     <li>",
"      To provide an opportunity for detailed observations of parent-child interaction by medical, nursing, social services, and behavioral sciences staff.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Medical neglect",
"    </span>",
"    &nbsp;&mdash;&nbsp;When medical neglect is a concern, the healthcare provider should make sure that the treatment plan is simplified, practical, and clearly communicated. Clear communication of the treatment plan may require written instructions or the services of a foreign language or sign language interpreter. The family should understand what to expect from the therapy, when to return for follow-up, and indications to contact or return to the healthcare provider before the follow-up appointment (eg, persistent or worsening symptoms) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The healthcare provider should provide support and arrange for follow-up (by phone, office visit, or visiting nurse) to review progress and adjust the treatment plan if necessary. The involvement of child protective services must be considered, particularly when there is serious harm or a risk of serious harm, and when less intrusive interventions have failed.",
"   </p>",
"   <p>",
"    All 50 states have laws requiring physicians to report child neglect to child protective services [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/4\">",
"     4",
"    </a>",
"    ]. Most states have exemptions to the child neglect laws for religious objection to medical care [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/33,37,38\">",
"     33,37,38",
"    </a>",
"    ]. However, the American Academy of Pediatrics (AAP) views such exemptions as potentially harmful to children and advocates that all children, regardless of parental religious beliefs, deserve effective medical treatment when such treatment is likely to prevent substantial harm, suffering, or death [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/37\">",
"     37",
"    </a>",
"    ]. In one review of 172 childhood fatalities associated with religion-motivated medical neglect, all but three of the cases would likely have had some benefit from clinical help [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/38\">",
"     38",
"    </a>",
"    ]. In 140 cases (81 percent), the deaths were due to conditions for which survival rates with medical care would have exceeded 90 percent; in another 18 cases (10 percent), the expected survival rates would have been &gt;50 percent.",
"   </p>",
"   <p>",
"    The AAP recommends that physicians respect parental religious beliefs and the role of parents in rearing their children, and seek to make collaborative decisions with families whenever possible [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/37\">",
"     37",
"    </a>",
"    ]. However, in circumstances in which the physician believes that parental religious convictions interfere with appropriate medical care that is likely to prevent substantial harm, suffering, or death, the AAP recommends that the physician request court authorization to override parental authority, or under circumstances of imminent threat to a child's life, to intervene over parental objections [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mandated reporting",
"    </span>",
"    &nbsp;&mdash;&nbsp;All 50 states have laws requiring physicians to report child neglect to child protective services [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/4\">",
"     4",
"    </a>",
"    ]. Most state laws regarding reporting of child maltreatment require certain professionals to report suspected cases of child abuse and neglect. These professionals include medical and mental health professionals, educators, child care providers, social service providers, and law enforcement personnel; some states also require clergy to report suspected child maltreatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/39\">",
"     39",
"    </a>",
"    ]. In the reporting of child abuse and neglect, the duty to report supersedes client-professional confidentiality. Most states provide immunity from legal liability for reporters in good faith. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10281?source=see_link\">",
"     \"Confidentiality in adolescent health care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most states, reports of child maltreatment are made orally by telephone or in person, and then followed by a written report, usually within 36 hours to five days after the oral report [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/39\">",
"     39",
"    </a>",
"    ]. The written report should include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The name, age, sex, and address of the child(ren)",
"     </li>",
"     <li>",
"      The nature and extent of the child's injuries or condition (in as much detail as possible)",
"     </li>",
"     <li>",
"      The name and address of the parent or other person who is responsible for the child",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each state designates specific agencies to receive and investigate reports of suspected child abuse and neglect. Many states have a toll-free number for reporting suspected child maltreatment (",
"    <a class=\"external\" href=\"file://www.childwelfare.gov/pubs/reslist/rl_dsp.cfm?rs_id=5&amp;rate_chno=11-11172\">",
"     www.childwelfare.gov/pubs/reslist/rl_dsp.cfm?rs_id=5&amp;rate_chno=11-11172",
"    </a>",
"    ). Child Protective Services (CPS) is the agency mandated by law in most states to conduct the initial evaluation of reports of child abuse and neglect and to offer rehabilitative services to families [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/39\">",
"     39",
"    </a>",
"    ]. In some states, police departments also may receive reports of child abuse or neglect. CPS is responsible for conducting family assessments, developing individualized case plans, providing direct services and coordinating services provided by other professionals, maintaining case records, reviewing case plans, and developing court reports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because child neglect encompasses both actual and potential harm and can be attributed to factors related to the child, parent, family, or community, it is sometimes difficult to know when to involve CPS. The author's guidelines for reporting include, but are not limited to, the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Child at risk of imminent harm from lack of supervision or protection",
"     </li>",
"     <li>",
"      Continuing medical or dental neglect despite the interventions mentioned above (eg, removing barriers to care, such as transportation, language, clarity of instructions, etc)",
"     </li>",
"     <li>",
"      Gross failure to provide adequate food, shelter, clothing, protection, education",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EMOTIONAL ABUSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emotional or psychological abuse is the most elusive and difficult to define of all types of child abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. It has been defined by the National Center of Child Abuse and Neglect as child abuse that results in impaired psychological growth and development [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/44\">",
"     44",
"    </a>",
"    ]. Emotional abuse is a repeated pattern of damaging interactions between parent(s) or caregiver(s) and the child that becomes typical of the relationship and conveys to the child that he or she is flawed, unloved, or unwanted. The pattern may be chronic or triggered by alcohol or other potentiating factors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Categories",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several categories of emotional or psychological abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/40,45\">",
"     40,45",
"    </a>",
"    ]. The behaviors of the caregiver that are described below constitute emotional abuse when they occur as part of a pattern of behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/2,41,43,45\">",
"     2,41,43,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Rejecting",
"      </strong>",
"      &ndash; Refusing to acknowledge the child's worth and the legitimacy of",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      needs; refusing to show affection",
"     </li>",
"     <li>",
"      <strong>",
"       Isolating",
"      </strong>",
"      &ndash; Denying the child normal social experiences and",
"      <span class=\"nowrap\">",
"       peer/familial",
"      </span>",
"      relationships, creating a sense in the child that",
"      <span class=\"nowrap\">",
"       he/she",
"      </span>",
"      is \"alone in the world\"; some parents may lock the child in a bedroom, closet, basement, or attic away from normal familial interaction",
"     </li>",
"     <li>",
"      <strong>",
"       Terrorizing",
"      </strong>",
"      &ndash; Verbal",
"      <span class=\"nowrap\">",
"       assault/threatening",
"      </span>",
"      of the child or his or her loved ones or objects; making the child feel unsafe; creating a climate of fear; convincing the child that \"the world is capricious and hostile.\" Weapons may be used to further terrorize the child.",
"     </li>",
"     <li>",
"      <strong>",
"       Ignoring",
"      </strong>",
"      &ndash; Psychological unavailability to the child, depriving him or her of essential stimulation and interaction; emotional starvation; lack of protection from danger",
"     </li>",
"     <li>",
"      <strong>",
"       Corrupting",
"      </strong>",
"      &ndash; Stimulating destructive, antisocial, or sexually exploitative behavior, reinforcing deviant behavior",
"     </li>",
"     <li>",
"      <strong>",
"       Verbal assault or spurning",
"      </strong>",
"      &ndash; Name-calling; sarcasm that erodes the child's self-esteem and reinforces negative self-image; singling out a child to criticize or punish; humiliating the child in public",
"     </li>",
"     <li>",
"      <strong>",
"       Overpressuring",
"      </strong>",
"      &ndash; Overly advanced expectation of the child's behavior and accomplishments; criticism of age-appropriate behavior as inadequate; comparing the child's behavior to other children as \"poor by comparison,\" resulting in a negative self-image and behavior disturbance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the categories above, emotional abuse may also result from child neglect, unreliable or inconsistent parenting (placing contradictory or ambivalent demands on the child), and witnessing intimate partner violence [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Child neglect'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31097?source=see_link\">",
"     \"Childhood exposure to intimate partner violence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The severity of emotional abuse is categorized according to the degree of malicious intent and the probability of emotional harm [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mild",
"      </strong>",
"      &ndash; Without malicious intent; no immediate danger of emotional harm. Management involves family therapy, parenting skills training, and supportive therapy for the child.",
"     </li>",
"     <li>",
"      <strong>",
"       Moderate",
"      </strong>",
"      &ndash; Inflicted with malicious intent or imminent probability of emotional harm, but not both. Family and interpersonal therapy is recommended.",
"     </li>",
"     <li>",
"      <strong>",
"       Severe",
"      </strong>",
"      &ndash; Emotional harm inflicted with malicious intent. In addition to individual and family therapy, removal of the child from the home may be necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emotional abuse is the most common form of child abuse since it occurs independently and is a component of all other forms of child abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/2,40,46\">",
"     2,40,46",
"    </a>",
"    ]. The true incidence of isolated emotional abuse is unknown, but estimates suggest a prevalence of approximately 10 percent based on self report by US and British children [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/10,43\">",
"     10,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are at risk for emotional abuse include those [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Whose parents are involved in a contentious divorce",
"     </li>",
"     <li>",
"      Who are unwanted or unplanned",
"     </li>",
"     <li>",
"      Whose parents are unskilled or inexperienced in parenting",
"     </li>",
"     <li>",
"      Whose parents engage in substance abuse",
"     </li>",
"     <li>",
"      Who are socially isolated",
"     </li>",
"     <li>",
"      Who are intellectually or emotionally handicapped",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;An emotionally abused child may display emotional disturbances (anxiety, depression, agitation, fearfulness), social withdrawal, running away from home, developmental delay, drug or alcohol abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/48\">",
"     48",
"    </a>",
"    ], or eating disorders including anorexia nervosa and bulimia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/42\">",
"     42",
"    </a>",
"    ]. The development of these problems may raise concern about emotional abuse among health care providers. Alternatively, the health care provider may observe a psychologically abusive caregiver-child relationship in the office, or may learn of the problem through the school or other family members [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Substantiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The substantiation of emotional abuse may be difficult and requires repeated observations of family interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/2\">",
"     2",
"    </a>",
"    ]. The observations should be documented as objectively as possible (ie, direct quotations of witnessed interactions). Collateral reports from schools, other professionals, child care workers, and others involved with the family can also be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/45\">",
"     45",
"    </a>",
"    ]. The involvement of a mental health provider can be helpful in uncertain cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sequelae of emotional abuse may become evident only much later in the child's life. The severity of the sequelae depends upon the intensity, extremeness, frequency, and chronicity of the abuse, and on mediating factors in the caregivers, child, and environment. The primary long-term sequelae of emotional abuse include poor adaptation to adult life, low self-esteem, marital and parenting difficulties, psychiatric disorders (antisocial and borderline personality disorders), substance abuse, and suicidal ideation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/42,45,49-53\">",
"     42,45,49-53",
"    </a>",
"    ]. One study of suicidal behavior reported that a history of physical abuse increased a subject's risk of suicide attempt fivefold, whereas a history of emotional abuse increased the risk by more than 12 times [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of emotional abuse begins with the physician's expression of concern for the child's emotional well-being [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/32\">",
"     32",
"    </a>",
"    ]. The discussion should be child-focused and nonaccusatory, emphasizing that emotional abuse is harmful to all family members and should be brought under control as quickly as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/2,32\">",
"     2,32",
"    </a>",
"    ]. Parents may not be aware that their criticism has reached a point of harm to the child. They may acknowledge stress or tension in the family that contributes to their lack of support [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/32\">",
"     32",
"    </a>",
"    ]. The physician should encourage the involvement of and offer to make a referral to an appropriate mental health specialist.",
"   </p>",
"   <p>",
"    The treatment of emotional abuse includes counseling and psychiatric therapy. Play therapy and therapeutic day care programs are available for younger children. Limited attention to the issue of emotional abuse and limited availability of psychiatric therapies for children present major obstacles in managing this problem. Data regarding the success of these interventions are not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Reporting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of Child Protective Services is recommended for emotional abuse with malicious intent or significant potential for imminent harm [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18408/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17112119\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17112222\">",
"    <span class=\"h2\">",
"     Child neglect",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Child neglect is defined as failure to provide for a child's basic physical, emotional, educational, or medical needs. Specific types of neglect include physical, emotional, educational, and medical neglect. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Child neglect'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The manifestations of child neglect include any or all of the following: nonorganic failure to thrive; developmental delay; starvation or dehydration; poor hygiene of child's body, clothes, or diapers; severe, untreated dental caries; school truancy; and injuries caused by lack of supervision (ingestions, burns, bathtub near-drownings, or other \"accidental\" injuries). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of child neglect requires that the healthcare provider convey to the family his or her concerns about the child's well-being and safety. The factors contributing to child neglect should be identified, prioritized, and addressed. The management can be enhanced by working with an interdisciplinary team. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The need for hospitalization in the neglected child is dependent upon several factors. Hospitalization may be warranted for the treatment of certain conditions (eg, ingestion, near-drowning) or may be indicated for the safety of the child. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Hospitalization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because child neglect encompasses both actual and potential harm and can be attributed to factors related to the child, parent, family, or community, it is sometimes difficult to know when to involve child protection services and other appropriate government agencies. The author's guidelines for reporting include, but are not limited to, the following (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Mandated reporting'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Child at risk of imminent harm from lack of supervision or protection",
"     </li>",
"     <li>",
"      Continuing medical or dental neglect despite the interventions designed to engage the family (eg, removing barriers to care such as transportation, language, clarity of instructions)",
"     </li>",
"     <li>",
"      Gross failure to provide adequate food, shelter, clothing, protection,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      education",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17112249\">",
"    <span class=\"h2\">",
"     Emotional abuse",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Emotional abuse is a repeated pattern of damaging interactions between parent(s) or caregiver(s) and the child that becomes typical of the relationship and conveys to the child that he or she is flawed, unloved, or unwanted and results in impaired psychological growth and development. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Findings associated with emotional abuse include anxiety, depression, agitation, fearfulness, social withdrawal, running away from home, developmental delay, drug or alcohol abuse, or eating disorders including anorexia nervosa and bulimia. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The health care provider may observe a psychologically abusive caregiver-child relationship in the office, or may learn of the problem through the school or other family members. The substantiation of emotional abuse may be difficult and requires repeated observations of family interactions. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Substantiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of emotional abuse includes counseling and psychiatric therapy. Involvement of Child Protective Services is recommended for emotional abuse that may pose imminent harm or is of malicious intent. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/1\">",
"      Wissow LS. Child abuse and neglect. N Engl J Med 1995; 332:1425.",
"     </a>",
"    </li>",
"    <li>",
"     Ludwig S. Child abuse. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1761.",
"    </li>",
"    <li>",
"     The Third National Incidence Study of Child Abuse and Neglect. National Center on Child Abuse and Neglect; US Department of Health anad Human Services, Washington DC, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/4\">",
"      Dubowitz H, Giardino A, Gustavson E. Child neglect: guidance for pediatricians. Pediatr Rev 2000; 21:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/5\">",
"      Centers for Disease Control and Prevention (CDC). Nonfatal maltreatment of infants--United States, October 2005-September 2006. MMWR Morb Mortal Wkly Rep 2008; 57:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/6\">",
"      Brayden RM, Altemeier WA, Tucker DD, et al. Antecedents of child neglect in the first two years of life. J Pediatr 1992; 120:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/7\">",
"      Helfer RE. The neglect of our children. Pediatr Clin North Am 1990; 37:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/8\">",
"      Golden MH, Samuels MP, Southall DP. How to distinguish between neglect and deprivational abuse. Arch Dis Child 2003; 88:105.",
"     </a>",
"    </li>",
"    <li>",
"     Wang CT, Daro D. Current trends in child abuse reporting and fatalities: The results of the 1997 Annual Fifty State Survey, Prevent Child Abuse America, Chicago 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/10\">",
"      Gilbert R, Widom CS, Browne K, et al. Burden and consequences of child maltreatment in high-income countries. Lancet 2009; 373:68.",
"     </a>",
"    </li>",
"    <li>",
"     McCurdy K, Daro D. Current trends in child abuse reporting and fatalities. The National Center on Child Abuse Prevention and Research, Working Paper No. 808. National Committee to Prevent Child Abuse, Chicago 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/12\">",
"      Berkowitz CD. Fatal child neglect. Adv Pediatr 2001; 48:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/13\">",
"      Margolin L. Fatal child neglect. Child Welfare 1990; 69:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/14\">",
"      Landen MG, Bauer U, Kohn M. Inadequate supervision as a cause of injury deaths among young children in Alaska and Louisiana. Pediatrics 2003; 111:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/15\">",
"      Gillham B, Tanner G, Cheyne B, et al. Unemployment rates, single parent density, and indices of child poverty: their relationship to different categories of child abuse and neglect. Child Abuse Negl 1998; 22:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/16\">",
"      Gaudin JM Jr, Polansky NA, Kilpatrick AC, Shilton P. Family functioning in neglectful families. Child Abuse Negl 1996; 20:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/17\">",
"      Accardo PJ, Whitman BY. Children of mentally retarded parents. Am J Dis Child 1990; 144:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/18\">",
"      Coohey C. Neglectful mothers, their mothers, and partners: the significance of mutual aid. Child Abuse Negl 1995; 19:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/19\">",
"      Harrington D, Black MM, Starr RH Jr, Dubowitz H. Child neglect: relation to child temperament and family context. Am J Orthopsychiatry 1998; 68:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/20\">",
"      Gaudin JM Jr, Polansky NA, Kilpatrick AC, Shilton P. Loneliness, depression, stress, and social supports in neglectful families. Am J Orthopsychiatry 1993; 63:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/21\">",
"      Polansky NA, Gaudin JM Jr, Ammons PW, Davis KB. The psychological ecology of the neglectful mother. Child Abuse Negl 1985; 9:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/22\">",
"      Coohey C. Home alone and other inadequately supervised children. Child Welfare 1998; 77:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/23\">",
"      Jessee SA. Orofacial manifestations of child abuse and neglect. Am Fam Physician 1995; 52:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/24\">",
"      American Academy of Pediatrics Committee on Early Childhood, Adoption, and Dependent Care: Oral and dental aspects of child abuse and neglect. Pediatrics 1986; 78:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/25\">",
"      Lavelle JM, Shaw KN, Seidl T, Ludwig S. Ten-year review of pediatric bathtub near-drownings: evaluation for child abuse and neglect. Ann Emerg Med 1995; 25:344.",
"     </a>",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. When to suspect child maltreatment. July 2009. file://www.nice.org.uk/CG89 (Accessed on September 21, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/27\">",
"      Dubowitz H, Papas MA, Black MM, Starr RH Jr. Child neglect: outcomes in high-risk urban preschoolers. Pediatrics 2002; 109:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/28\">",
"      Buchanan A, Oliver JE. Abuse and neglect as a cause of mental retardation: a study of 140 children admitted to subnormality hospitals in Wiltshire. Br J Psychiatry 1977; 131:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/29\">",
"      Kendall-Tackett KA, Eckenrode J. The effects of neglect on academic achievement and disciplinary problems: a developmental perspective. Child Abuse Negl 1996; 20:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/30\">",
"      Allen RE, Oliver JM. The effects of child maltreatment on language development. Child Abuse Negl 1982; 6:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/31\">",
"      Kotch JB, Lewis T, Hussey JM, et al. Importance of early neglect for childhood aggression. Pediatrics 2008; 121:725.",
"     </a>",
"    </li>",
"    <li>",
"     Ludwig S, Rostain A. Family function and dysfunction. In: Developmental-Behavioral Pediatrics, 4th, Carey WB, Crocker AC, Coleman WL, et al.  (Eds), Saunders Elsevier, Philadelphia 2009. p.103.",
"    </li>",
"    <li>",
"     Dubowitz H, Finkel MA. Child abuse and neglect. In: Primary Pediatric Care, 4th, Hoekelman RA.  (Ed), Mosby, St. Louis 2001. p.682.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/34\">",
"      Jenny C, Committee on Child Abuse and Neglect, American Academy of Pediatrics. Recognizing and responding to medical neglect. Pediatrics 2007; 120:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/35\">",
"      Dubowitz H. Preventing child neglect and physical abuse: a role for pediatricians. Pediatr Rev 2002; 23:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/36\">",
"      Medical necessity for the hospitalization of the abused and neglected child. American Academy of Pediatrics. Committee on Hospital Care and Committee on Child Abuse and Neglect. Pediatrics 1998; 101:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/37\">",
"      Religious objections to medical care. American Academy of Pediatrics Committee on Bioethics. Pediatrics 1997; 99:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/38\">",
"      Asser SM, Swan R. Child fatalities from religion-motivated medical neglect. Pediatrics 1998; 101:625.",
"     </a>",
"    </li>",
"    <li>",
"     DePanfilis D, Salus MK. A coordinated response to child abuse and neglect: A basic manual. National Center on Child Abuse and Neglect; US Department of Health and Human Services: Administration for Children and Familiies, Washington, DC 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/40\">",
"      Hamarman S, Bernet W. Evaluating and reporting emotional abuse in children: parent-based, action-based focus aids in clinical decision-making. J Am Acad Child Adolesc Psychiatry 2000; 39:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/41\">",
"      Nelms BC. Emotional abuse: helping prevent the problem. J Pediatr Health Care 2001; 15:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/42\">",
"      Kent A, Waller G. Childhood emotional abuse and eating psychopathology. Clin Psychol Rev 2000; 20:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/43\">",
"      Hibbard R, Barlow J, Macmillan H, et al. Psychological maltreatment. Pediatrics 2012; 130:372.",
"     </a>",
"    </li>",
"    <li>",
"     National Center of Child Abuse and Neglect. National Center of Child Abuse and Neglect, Washington, DC 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/45\">",
"      Kairys SW, Johnson CF, Committee on Child Abuse and Neglect. The psychological maltreatment of children--technical report. Pediatrics 2002; 109:e68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/46\">",
"      Kaplan SJ, Pelcovitz D, Labruna V. Child and adolescent abuse and neglect research: a review of the past 10 years. Part I: Physical and emotional abuse and neglect. J Am Acad Child Adolesc Psychiatry 1999; 38:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/47\">",
"      Hart SN, Brassard MR. A major threat to children's mental health. Psychological maltreatment. Am Psychol 1987; 42:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/48\">",
"      Garbarino J. Psychological child maltreatment. A developmental view. Prim Care 1993; 20:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/49\">",
"      Campo AT, Rohner RP. Relationships between perceived parental acceptance-rejection, psychological adjustment, and substance abuse among young adults. Child Abuse Negl 1992; 16:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/50\">",
"      Vissing YM, Straus MA, Gelles RJ, Harrop JW. Verbal aggression by parents and psychosocial problems of children. Child Abuse Negl 1991; 15:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/51\">",
"      Mullen PE, Martin JL, Anderson JC, et al. The long-term impact of the physical, emotional, and sexual abuse of children: a community study. Child Abuse Negl 1996; 20:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/52\">",
"      Johnson JG, Cohen P, Smailes EM, et al. Childhood verbal abuse and risk for personality disorders during adolescence and early adulthood. Compr Psychiatry 2001; 42:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18408/abstract/53\">",
"      Dube SR, Anda RF, Felitti VJ, et al. Childhood abuse, household dysfunction, and the risk of attempted suicide throughout the life span: findings from the Adverse Childhood Experiences Study. JAMA 2001; 286:3089.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6603 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-403C6C9E42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_62_18408=[""].join("\n");
var outline_f17_62_18408=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17112119\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHILD NEGLECT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Physical neglect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Emotional neglect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Educational neglect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Medical neglect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Hospitalization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Medical neglect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mandated reporting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EMOTIONAL ABUSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Categories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Substantiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Sequelae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Reporting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17112119\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17112222\">",
"      Child neglect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17112249\">",
"      Emotional abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6603\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6603|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?18/43/19135\" title=\"algorithm 1\">",
"      Epidemiologic algorithm neglect",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6603|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/14/43245\" title=\"table 1\">",
"      Causes of failure to thrive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/52/11083\" title=\"table 2\">",
"      Evaluation emotional neglect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/20/4429\" title=\"table 3A\">",
"      Child abuse neglect resources A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/25/1437\" title=\"table 3B\">",
"      Child abuse neglect resources B",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31097?source=related_link\">",
"      Childhood exposure to intimate partner violence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/2/10281?source=related_link\">",
"      Confidentiality in adolescent health care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/12/14538?source=related_link\">",
"      Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_62_18409="Primary operative management of hand burns";
var content_f17_62_18409=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary operative management of hand burns",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/62/18409/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/62/18409/contributors\">",
"     Samuel P Mandell, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/62/18409/contributors\">",
"     Matthew B Klein, MD, MS, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/62/18409/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/62/18409/contributors\">",
"     Marc G Jeschke, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/62/18409/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/62/18409/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/62/18409/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 80 percent of severe burn injuries involve the hand, and thus have a tremendous impact on daily function and quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/1\">",
"     1",
"    </a>",
"    ]. Effective treatment of hand burns requires a multifaceted and interdisciplinary approach that includes burn surgeons, plastic surgeons, rehabilitation physicians, and physical therapists.",
"   </p>",
"   <p>",
"    The initial surgical approach to the patient with a burned hand, including the primary and secondary assessment and primary operative management are discussed here. Surgical techniques used for primary coverage of burns (eg, skin grafts, free flaps) are also used for reconstruction of burns. The principles of reconstruction and operative procedures for secondary or delayed reconstruction of burns to the hands are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15882?source=see_link&amp;anchor=H17954407#H17954407\">",
"     \"Principles of burn reconstruction: Extremities and regional nodal basins\", section on 'Hand'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of the patient with a hand burn begins with a thorough history and physical examination. Information about the mechanism of injury and the circumstances surrounding the injury may provide insight into the potential depth of the burn and healing capacity. The patient's hand dominance, occupation, and prior hand injuries should also be ascertained.",
"   </p>",
"   <p>",
"    The focus of the physical examination is to estimate the severity and depth of injury, as well as the viability of the hand and digits. Adequate hand perfusion is present if the radial and ulnar pulses are palpable; Doppler assessment should be done if pulses are not palpable. Each digit should be evaluated separately for perfusion by Doppler [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients at greatest risk for loss of perfusion are those that have full thickness burns, circumferential burns, or associated crush injuries and lacerations.",
"   </p>",
"   <p>",
"    Signs of poor perfusion include [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Capillary refill time &gt;2 seconds",
"     </li>",
"     <li>",
"      Cold hand to touch",
"     </li>",
"     <li>",
"      Absence of Doppler signal",
"     </li>",
"     <li>",
"      Central core-to-extremity temperature difference greater than 7 degrees Celsius",
"     </li>",
"     <li>",
"      Muscle compartment pressures of &gt;30 mmHg",
"     </li>",
"     <li>",
"      Oxygen saturation &lt;90 percent or a 6 percent difference between a healthy site and the injured site, with caution as low readings may be due to vasoconstriction rather than compression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dressings should be applied to fingers individually. The thickness of the dressings should not interfere with range of motion and use of the hand. Splinting is reserved for patients who have deep burns and a clawed deformity or those who have a progressively diminished range of motion. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Post-operative care'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients are encouraged to use their injured hands to minimize swelling and loss of function. All patients are started early on an aggressive range of motion physical therapy program. A passive range of motion exercise program is started for sedated or otherwise unresponsive patients.",
"   </p>",
"   <p>",
"    The primary treatment goals include [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prevention of additional or deeper injuries",
"     </li>",
"     <li>",
"      Rapid wound closure",
"     </li>",
"     <li>",
"      Preservation of active and passive motion",
"     </li>",
"     <li>",
"      Prevention of infection or loss of functional structures",
"     </li>",
"     <li>",
"      Early functional rehabilitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These goals are achieved by applying the following principles:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Determination of dimension and depth of the burn",
"     </li>",
"     <li>",
"      Escharotomy",
"     </li>",
"     <li>",
"      Application of adequate wound dressings",
"     </li>",
"     <li>",
"      Decision upon conservative or surgical treatment",
"     </li>",
"     <li>",
"      Surgical management (eg, excision, skin grafts, skin substitutes, free flaps)",
"     </li>",
"     <li>",
"      Early hand therapy with splinting",
"     </li>",
"     <li>",
"      Functional rehabilitation and physical therapy by early active and passive motion",
"     </li>",
"     <li>",
"      Secondary and tertiary corrections as required",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of unresolved controversy regarding the optimal treatment of hand burns, the following research priorities were developed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Optimal management of the exposed tendon",
"     </li>",
"     <li>",
"      Benefit of skin substitutes",
"     </li>",
"     <li>",
"      Optimal surgical approach to prevent and treat web space contractures",
"     </li>",
"     <li>",
"      Optimal timing and components of physical therapy (eg, exercises and modalities)",
"     </li>",
"     <li>",
"      Identify risk factors that influence the outcome of partial thickness skin graft coverage",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SECONDARY MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to operate on hand burns and which procedure to choose depends on the type of injury, injury severity, and availability of tissue for coverage. Given the complex nature of the hand, referral to a designated burn center should be made for surgical management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37479?source=see_link\">",
"     \"Treatment of minor thermal burns\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=see_link\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neurovascular compromise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurovascular compromise is one of the major complications of burns to the hand. It can result from formation of a circumferential eschar or from increased pressure in the muscle compartment due to large volumes of resuscitation fluid. Decompressive therapies include escharotomy, fasciotomy, and peripheral nerve release. There is insufficient evidence to support a single standard approach [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/2,9\">",
"     2,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Escharotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Escharotomy restores perfusion to the hand by releasing the constricting eschar. In patients with signs of poor perfusion, immediate escharotomy should be performed to salvage the hand [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/2,10\">",
"     2,10",
"    </a>",
"    ]. By the time radial and ulnar pulses disappear, tissue ischemia is well advanced [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/10\">",
"     10",
"    </a>",
"    ]. For compartment pressures between 25 and 30 mmHg, either escharotomy or close and continued monitoring for signs of vascular compromise is a reasonable approach.",
"   </p>",
"   <p>",
"    Expert opinion and experience guide decision making in these difficult situations. Continued monitoring, reassessment, and transfer to a burn center if possible will minimize the risk of serious complications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional indications for escharotomies resulting from a full thickness burn include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pain",
"     </li>",
"     <li>",
"      Resistance to passive straightening of fingers",
"     </li>",
"     <li>",
"      Hand tense to palpation",
"     </li>",
"     <li>",
"      Circumferential burn [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Escharotomy can be performed at the",
"    <span class=\"nowrap\">",
"     forearm/wrist",
"    </span>",
"    (conventional) alone or with digital escharotomy. A randomized trial comparing the two approaches in 26 circumferentially burned hands found that conventional escharotomy was associated with a three-fold higher risk of developing necrotic phalanges than conventional therapy plus digital escharotomy (20.8 versus 7.1 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/12\">",
"     12",
"    </a>",
"    ]. Although the digital escharotomy incisions healed without complications in this study, recognized complications of this procedure include nerve damage, tendon injury, and blood loss.",
"   </p>",
"   <p>",
"    It is not our practice to perform digital escharotomies, as damage to key superficial structures likely outweighs the potential benefit. If a digital escharotomy is performed, the incision should be performed on the ulnar side of the digit. An escharotomy performed on the radial side of the digit may result in damage to the vascular nerve bundle leading to impaired sensitivity and function.",
"   </p>",
"   <p>",
"    After escharotomy, the hand is clinically evaluated for restoration or failure of perfusion. If perfusion is not restored, then fasciotomy is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Fasciotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A fasciotomy releases the tension or pressure in a muscle compartment by incising the fascia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/11\">",
"     11",
"    </a>",
"    ]. Expert opinion and experience guide the decision to perform the procedure.",
"   </p>",
"   <p>",
"    Indications for fasciotomy include [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/4,10,13\">",
"     4,10,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Failure of escharotomies to restore perfusion",
"     </li>",
"     <li>",
"      Compartment pressure exceeds 30 mmHg",
"     </li>",
"     <li>",
"      Compartment pressure within 10 to 20 mmHg of diastolic pressure",
"     </li>",
"     <li>",
"      Decrease in peripheral pulse-oximetry to &lt;90 percent",
"     </li>",
"     <li>",
"      High voltage (&gt;1000 Volts) electrical injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There continues to be controversy over the role of surgical debridement in electrical burn wounds. At our institution, we favor initial resuscitation and wound care, reserving fasciotomies and debridement for patients with clinical signs of a compartment syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/4,14\">",
"     4,14",
"    </a>",
"    ]. By avoiding early fasciotomy, if possible, tissue can be preserved for later coverage. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Surgical procedures'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Peripheral nerve release",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decompressive therapies are performed for signs and symptoms of median, ulnar,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radial nerve compression. Symptoms include a loss of sensation, loss of motor function, and paresthesias. Carpal tunnel release may be required if median nerve symptoms, characterized by diminished grip or pinch, develop in a previously normally functioning hand [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32822?source=see_link\">",
"     \"Surgery for carpal tunnel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms of ulnar nerve compression, characterized by diminished flexion of the wrist and digits, can be alleviated with a release of Guyon's canal. Symptoms of radial nerve compression include diminished extension and abduction of the wrist and digits and paresthesias. Incising the deep interosseous fascia on the dorsal hand releases the entrapped nerve. Sensory symptoms may be difficult to assess in the burn victim and the focus should be on the motor function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Amputation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases of severe vascular, tendon, bone, or joint damage, it may not be possible to salvage the hand. If there is a question regarding viability, amputation may be delayed or tissue flap coverage attempted. If a flap is performed and fails, delayed amputation is an option. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15882?source=see_link&amp;anchor=H25050215#H25050215\">",
"     \"Principles of burn reconstruction: Extremities and regional nodal basins\", section on 'Amputated digits'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Tissue loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of the tissue loss depends on the depth and type of the burn. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4326?source=see_link\">",
"     \"Classification of burns\"",
"    </a>",
"    .) Wound coverage with either skin grafts, tissue flaps, or dermal matrices is an important component of the process of regaining function of the hand. Skin grafts or tissue flap coverage are generally used in deep second degree or full thickness burns in approximately 14 to 21 days after burn injury. In comparison, superficial burns are most likely to heal with local non-operative wound care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Excision and skin grafting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional surgical approach to burns capable of healing within two to three weeks, such as superficial and intermediate partial thickness burns, is to manage the burn with non-operative local wound care including debridement and dressing changes, and aggressive range of motion exercises. A prospective study of 164 burned hands found that hands with superficial burns responded equally well to operative or non-operative management when evaluated for preservation of hand function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Deep second degree or full thickness burns are not likely to heal within two to three weeks with non-operative treatment. These burns are managed with excision of the necrotic tissue and grafting for coverage of the burn [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/15-19\">",
"     15-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective review of 116 burned hands showed early excision and grafting within the first four to six days post burn significantly reduced the risk of functionally debilitating scars compared to delayed grafting (7.7 versus 36.8 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective trial of patients with deep second and third degree burns of the hands treated by early (2 to 12 days post burn) excision and grafting (n = 25) demonstrated no significant difference in hand function, deformities, scaring, and patient satisfaction compared to burned hands treated with initial conservative management of topical antibiotics and dressings and delayed excision and grafting (4 to 8 weeks post burn, n = 25) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/20\">",
"       20",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A caveat to comparing these studies is that there is no consensus on the definition of early and late surgical excision and grafting of deep hand burns. In the absence of high quality prospective data, early excision and skin grafting within the first four to six days appears to be the treatment of choice. &nbsp;",
"   </p>",
"   <p>",
"    Burns must be re-evaluated frequently as the burn process is dynamic and it is difficult to distinguish partial from full thickness burns. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Surgical procedures'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=see_link\">",
"     \"Hypermetabolic response to severe burn injury: Recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Burns of the palms warrant special consideration. The skin of the palm is very thick with excellent healing potential. Hence, palm burns will generally heal without grafting and early excision should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/7,21\">",
"     7,21",
"    </a>",
"    ]. Aggressive physical therapy must be undertaken to prevent palmar contractures [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Tissue flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dorsal skin of the hand is relatively thin and, therefore, deep burns often injure or expose underlying structures such as tendons, joints, and bone. Debridement of deep burns may also result in exposure of these structures. These wounds, in the absence of periosteum or paratendon, are not amenable to coverage with skin grafts and tissue flaps are required [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The free forearm fascial flap, with radial artery preservation or modifications of the blood supply, provides an excellent option for vascularized coverage and is the procedure of choice [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. These versatile and reliable flaps include skin, subcutaneous tissue, the underlying fascia, and septocutaneous perforating branches of the radial or ulnar artery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/24\">",
"     24",
"    </a>",
"    ]. The success rate for overall viability is excellent. Small series of case reports identify partial or superficial flap loss requiring a skin graft in approximately 15 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Long-term results reveal good flap durability and elasticity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, with extensive burns, the forearm tissue may not be available and distant flaps, either pedicled or free flaps, may be required for tissue coverage [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/22,28\">",
"     22,28",
"    </a>",
"    ]. In a retrospective review of 1339 burn injuries over five years, only six patients (0.4 percent), required a distant pedicle flap for coverage of the burned hand [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/22\">",
"     22",
"    </a>",
"    ]. Five of these six patients hand complete healing of the wound and one had partial loss of the flap. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Surgical procedures'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SURGICAL ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hand has 10 osteofascial compartments: four dorsal interossei, three volar interossei, the thenar muscles, hypothenar muscles, and the adductor pollicis (",
"    <a class=\"graphic graphic_figure graphicRef74598 \" href=\"UTD.htm?32/4/32840\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/6\">",
"     6",
"    </a>",
"    ]. The radial and ulnar arteries, and the superficial and deep palmar arches provide the blood supply to the hand. In many patients, the hand is viable with only one artery intact (",
"    <a class=\"graphic graphic_figure graphicRef74598 \" href=\"UTD.htm?32/4/32840\">",
"     figure 1",
"    </a>",
"    ). The median, radial, and ulnar nerves provide innervation to the hand. These nerves give rise to the digital nerves that run laterally in each digit along with the digital artery (",
"    <a class=\"graphic graphic_figure graphicRef52343 \" href=\"UTD.htm?12/59/13236\">",
"     figure 2",
"    </a>",
"    ). The hand also has unique properties in terms of skin structure. The dorsal hand has thin, pliable skin that allows for flexion. The palmar surface, however, is thick and tightly held to underlying structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of escharotomy, all of the following procedures should be performed in the operating room under a general or regional anesthetic. Emergent escharotomy may be performed at the bedside in the intensive care unit (ICU) with appropriate pain and anxiolysis medication.",
"   </p>",
"   <p>",
"    Intra-operative monitoring is guided by the overall extent of the burn injury. While no specific monitoring is required for hand burns, patients may have extensive and severe burns that require aggressive resuscitation and management [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=see_link\">",
"     \"Hypermetabolic response to severe burn injury: Recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SURGICAL PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decompressive therapies include an escharotomy, fasciotomy, and release of peripheral nerve entrapment. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Secondary management'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Escharotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Escharotomy incisions are made in a longitudinal fashion with either a scalpel or electrocautery through the full thickness of the eschar (",
"    <a class=\"graphic graphic_picture graphicRef51668 \" href=\"UTD.htm?29/45/30419\">",
"     picture 1",
"    </a>",
"    ). The subcutaneous tissue should not be incised. The procedure is not painful when performed correctly. The eschar itself is insensate, so severe pain during an escharotomy should prompt immediate re-evaluation of the appropriateness of the procedure or the technique.",
"   </p>",
"   <p>",
"    Axial incisions are made at both the radial and the ulnar aspects of the wrist. Longitudinal escharotomies of the digits are performed on the midlateral side of the digit; however, as discussed above, their use is controversial because of potential injury to digital nerves and arteries, thus clinical judgment is warranted (",
"    <a class=\"graphic graphic_figure graphicRef64145 \" href=\"UTD.htm?41/40/42625\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/12\">",
"     12",
"    </a>",
"    ]. Perfusion to the digits and hand should be reassessed immediately after escharotomy. If circulation remains compromised, additional escharotomies are performed over the intermetacarpal spaces, without exposing the tendons. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Secondary management'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Fasciotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A fasciotomy is performed if an escharotomy fails to restore perfusion. Carpal tunnel release is an example of a fasciotomy to release an entrapped medial nerve. As the constricting fascia is released, viability of muscle is assessed and debridement of necrotic tissue is performed. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Secondary management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A complete hand fasciotomy consists of four incisions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radial side of the thumb, which releases the thenar compartment.",
"     </li>",
"     <li>",
"      Dorsal incision over the index finger metacarpal, which releases the first and second dorsal interossei, volar interossei, and adductor pollicis.",
"     </li>",
"     <li>",
"      Dorsal incision over the fourth (ring) finger metacarpal, which releases the third and fourth interossei and volar interossei.",
"     </li>",
"     <li>",
"      Ulnar side of the small finger, which releases the hypothenar muscles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Excision and grafting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because excision proceeds tangentially across blood vessels, bleeding can be significant and a tourniquet should be used to minimize blood loss. Excision may be performed with a Goulian knife, though this is difficult in certain areas such as web spaces. A high-pressure water jet system is useful in these areas (",
"    <a class=\"graphic graphic_picture graphicRef56945 \" href=\"UTD.htm?16/54/17252\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Underlying structures such as tendons, joints, or bones should not be exposed. If small areas are exposed, surrounding periosteum should be sutured in place for coverage.",
"   </p>",
"   <p>",
"    Adequate hemostasis is essential to preventing hematoma formation and graft loss. Once the excision is complete, epinephrine (1:10,000) soaked non-adhesive dressings and epinephrine soaked laparotomy pads are applied prior to deflating the tourniquet and left in place for 10 minutes to achieve hemostasis. Tissue viability is confirmed by releasing the tourniquet to observe bleeding.",
"   </p>",
"   <p>",
"    Skin grafting of the hand is performed using split thickness skin grafts from unburned donor sites [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/10\">",
"     10",
"    </a>",
"    ]. As hand function and aesthetic outcome are critical in hand burn management, sheet grafts are preferable to meshed grafts and can be harvested from the back, scalp, or thigh. Skin is harvested at a thickness of 0.012 inches for the dorsal hand and digits for adults and 0.008 inches for children. For the palm, we utilize full thickness grafts (particularly in children) when a donor site is available, and if not, we use thick split thickness grafts of 0.016 to 0.018 inches [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/21,33,34\">",
"     21,33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To prevent shearing of the grafts, the hand is grafted in the position that is maintained in the splint. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Positioning'",
"    </a>",
"    below.) Grafts are affixed with absorbable suture, using fibrin glue to minimize the number of sutures required. Following placement, the grafted hand is dressed first with a non-adherent dressing, and then with a thick gauze wrap, followed by a custom fabricated splint. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Post-operative care'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Dermal regeneration templates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following excision of the burn, the wound bed is evaluated to determine if it is suitable for a skin graft. The wound bed should be assessed for thoroughness of the debridement, vascularity, and exposure of bone, joint, or tendon. A cadaver allograft can be used as temporary wound cover as a test of the viability of the wound bed. Adherence of the allograft to the wound bed within five days of coverage indicates that the wound is ready for a skin graft. If the allograft is not adherent to the base, then the wound will not heal with a skin graft.",
"   </p>",
"   <p>",
"    Several dermal regeneration templates (dermal substitutes) are available to use as an adjunct. These substitutes will not create a viable wound bed, and should not be used if viability is questioned. Dermal regeneration templates are not substitutes for flap coverage in instances of extensive tendon or bone exposure. Use of dermal substitutes also allows for coverage by a thinner skin grafts.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Integra&reg; &mdash; Integra&reg; is a bilayer of bovine tendon collagen and glycosaminoglycan with silicon \"epidermis\". After excision, Integra&reg; is placed over the wound bed and allowed to incorporate for approximately two weeks. In a second procedure, the outer silicone layer is removed and a thin (0.006\") split thickness skin graft is placed over the \"neo-dermis\". In one study, Integra&reg; was applied to 216 clean and surgically excised burn wounds in 13 centers in the US [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/35\">",
"       35",
"      </a>",
"      ]. Two to three weeks later, the dermal layer regenerated and was subsequently covered with a thin epidermal skin graft. The median take rate of the Integra&reg; was 95 percent and the median take rate of the skin graft was 98 percent.",
"     </li>",
"     <li>",
"      AlloDerm&reg; &mdash; AlloDerm&reg; is lyophilized human dermis with the cellular components removed. AlloDerm&reg; is placed over excised wounds and the wound is allowed to granulate for approximately two weeks. The AlloDerm&reg; is then removed and split thickness skin grafts are placed. There are small case series describing the use of AlloDerm&reg; for burn wound management [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/36-38\">",
"       36-38",
"      </a>",
"      ]. In the largest of these, tissue loss from burns or other trauma revealed a successful graft take in 26 of 27 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Matriderm&reg; &mdash; Matriderm&reg; is a three-dimensional collagen and elastin matrix derived from bovine tendon and ligament. A small case series using Matriderm&reg; as a one-stage dermal replacement in severe hand burns revealed an overall take rate of 97 percent, excellent pliability of the grafted area, and full range of motion [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Tissue Flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposed tendon or bone are best treated by coverage with a tissue flap [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/7\">",
"     7",
"    </a>",
"    ]. Skin grafts should not be used as coverage of these structures.",
"   </p>",
"   <p>",
"    The following is a brief description of commonly used flaps.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radial forearm fasciocutaneous flap or fascial flap &mdash; Radial forearm fasciocutaneous flaps or fascial flaps are used as coverage of exposed tendons, bones, or joints (",
"      <a class=\"graphic graphic_picture graphicRef80774 \" href=\"UTD.htm?11/37/11863\">",
"       picture 3",
"      </a>",
"      ). A Doppler ultrasound, rather than the Allen test [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/40\">",
"       40",
"      </a>",
"      ], is performed to ensure adequate blood flow to the hand through the palmar arch as these flaps are based on the radial artery [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/40\">",
"       40",
"      </a>",
"      ]. A skin graft is required either for the donor site if a fasciocutaneous flap is used, or for the flap if fascia only is used.",
"     </li>",
"     <li>",
"      Distally based posterior interosseous flap (DBPIF) &mdash; The posterior interosseous flap is a fasciocutaneous flap harvested from the dorsal aspect of the forearm [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/41\">",
"       41",
"      </a>",
"      ]. The principle advantage of this flap is that neither of the major vessels perfusing the hand is disrupted. This is especially important if either the radial or the ulnar artery have already been injured. In such cases, DBPIF remains an option for skin coverage. The most common variation in the anatomy of these vessels is absence or hypoplasia; therefore, a small incision should be made to explore the vessels prior to flap elevation.",
"     </li>",
"     <li>",
"      Abdominal and groin flaps (distant pedicled flaps) &mdash; A pedicled flap is tissue that is transposed to a recipient site while still attached at the base to the donor site. The pedicle serves as a conduit for blood supply. The abdomen or groin pedicled flaps are options for skin coverage when local flaps are not feasible due to the extent of injury to the extremity (",
"      <a class=\"graphic graphic_picture graphicRef81818 \" href=\"UTD.htm?16/63/17395\">",
"       picture 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/10\">",
"       10",
"      </a>",
"      ]. The transfer of tissue as a pedicled flap is a two-step procedure that includes creating the flap and covering the burn, then allowing time for vascularization of the wound and subsequent division from the base of the pedicled flap.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      As the first stage of the procedure, the skin, subcutaneous tissue, and fascia are raised on a pedicle from the groin or abdomen, and secured to the burned hand. The hand is retained in the in-situ position on the abdomen or groin for two to three weeks prior to flap division. Indocyanine-green fluorescence is used to assess flap viability, if needed [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At the second stage of the procedure, the flap is either divided completely from the donor site or a Crane procedure is performed in which only the fascia is transferred and the skin and subcutaneous tissue are re-sutured to the donor site [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/43\">",
"       43",
"      </a>",
"      ]. This approach requires grafting of the fascia on the hand, but provides a viable thin and supple coverage as a base for an autograft.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Free tissue transfer &mdash; Free tissue transfer, or free flaps, is the transfer of tissue from one location to another, along with its blood supply, and detached from the primary location. Free flaps provide a single-step approach to hand coverage in cases where there are no local tissue coverage options. Fascial flaps from the contralateral radial forearm fascia, temporoparietal fascia, dorsalis pedis fascia, anterolateral thigh, and muscle flaps from the serratus anterior, rectus abdominis, and gracilis are used as donor sites [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/28,44\">",
"       28,44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Biobrane&trade; glove",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biobrane&trade; is a bilaminate, semipermeable silicone membrane bound to a layer of nylon with porcine collagen. It is an alternative to conventional dressing changes for superficial partial thickness burns, but cannot be used to treat deeper burns [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Biobrane is available as a glove for burned hands, and is applied to clean wounds that present within 24 hours of injury.",
"   </p>",
"   <p>",
"    Successful use of this modality requires a clean wound bed that is obtained often with use of a regional or general anesthetic [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/46\">",
"     46",
"    </a>",
"    ]. The glove is applied to the wound bed an secured with adhesive tape. For children, sheets of Biobrane can be tailored to fit smaller hands [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/47\">",
"     47",
"    </a>",
"    ]. The glove can be removed once epithelialization occurs. Biobrane has been shown to reduce pain levels, healing times, and hospital stays [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Vacuum assisted closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vacuum assisted closure (VAC) devices are topical negative pressure systems used to promote healing in acute and chronic wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/49-56\">",
"     49-56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link\">",
"     \"Negative pressure wound therapy\"",
"    </a>",
"    .) The VAC also can serve as a bolster for grafts.",
"   </p>",
"   <p>",
"    Data on the efficacy of this VAC devices for the care of burns of the hand is promising but limited:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective trial compared use of the VAC negative pressure system with a standard bolster dressing over two weeks in 22 adult patients with skin grafted burn wounds [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/53\">",
"       53",
"      </a>",
"      ]. Compared to the standard bolster group, 75 percent of wounds treated with VAC had a greater than or equivalent degree of re-epithelialization and 85 percent had a better than or equivalent graft quality.",
"     </li>",
"     <li>",
"      A prospective, multicenter trial evaluated VAC with conventional conservative management in 11 patients with bilateral hand burns [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/57\">",
"       57",
"      </a>",
"      ]. The patients served as their own controls. The hand treated with the VAC device had less connective tissue edema, improved microcirculation by dynamic laser-fluorescence videography, and faster wound healing for both superficial and deep burns.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     POST-OPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following placement of the grafts, the operative site is dressed with a non-adherent dressing, thick gauze wrap, and a custom fabricated splint. Dressings are removed on post-operative day one for inspection of the wound for a hematoma or seroma. If present, a small incision is used to incise the graft over the fluid collection. Daily inspection continues until there are no further fluid collections. The hand remains in dressings and immobilized until day five, at which time range of motion exercises are started [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Physical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is our practice to begin physical therapy within 24 hours after injury regardless of the extent of the burn. Initially, the focus is on range of motion (ROM) and reduction of edema. Pain medications are provided, but should not impede efforts at physical therapy. If the patient cannot actively participate in therapy, passive ROM should be performed. Throughout hospitalization, the patient is educated and directed toward independence with physical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Edema management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevation of the hand is one primary method of edema prevention. Hand exercises can activate muscle pumping within the hand and help reduce edema. In some cases, external pressure through self-adhesive wraps or bandages may be useful [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splinting is used when range of motion (ROM) is limited and contracture of the hand is likely to occur. The hand should be immobilized with wrist extension, metacarpophalangeal joint (MCP) flexion, proximal interphalangeal joint (PIP), and distal interphalangeal joint (DIP) extension and thumb palmar abduction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/58\">",
"     58",
"    </a>",
"    ]. The first web space must be maintained. In cases of palmar burns, a pan-extension splint is used. Patients are instructed to continue ROM exercises, even with a splinting program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are not discharged until they are self sufficient with wound care and physical therapy routines, including application of splints, if needed. Outpatient regimens may vary, but remain multidisciplinary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scarring and contracture with loss of hand function remain serious problems, even with aggressive acute burn care. Split thickness skin grafts contract 30 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/60\">",
"     60",
"    </a>",
"    ]. Even with early grafting, debilitating contractures occur in 7.7 percent of burned hands [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Scarring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pressure application is the mainstay of early scar management. In the early phase when shear forces from gloves cannot be tolerated on fragile skin grafts, self-adhesive bandages are used. As healing progresses, prefabricated pressure gloves are used, followed by custom-made pressure garments if needed. Inserts are used to ensure pressure is applied to appropriate areas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/61\">",
"     61",
"    </a>",
"    ]. The time for scar tissue to mature is 12 to 24 months. Therefore, surgical correction should generally be deferred until 12 months post-injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Contracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four main types of contracture flexion (",
"    <a class=\"graphic graphic_picture graphicRef50506 \" href=\"UTD.htm?33/7/33908\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Contracture of the digits",
"     </li>",
"     <li>",
"      Palmar contracture",
"     </li>",
"     <li>",
"      Dorsal hand contracture",
"     </li>",
"     <li>",
"      Syndactyly",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Contractures affecting the deep structures are surgically released and grafts or flaps cover the defects. Prior to considering procedures for contracture release, patient compliance with a physical therapy regimen is essential. If patients do not participate, the endeavor is doomed to failure. Secondary surgery, in the form of contracture release, is not a substitute for an aggressive physical therapy regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/10,58\">",
"     10,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to the reconstruction operation, the functional deficit, the structure causing the problem, and available options for tissue coverage of the defect are addressed. The discussion with the patient focuses on reasonable expectations and outcome. The final portion of the operative planning includes timing of procedures. If both hands require reconstruction, it is more practical for the patient to operate on one hand at a time. In addition, if one correction will require aggressive use of the digits, it should not be performed at the same time as a procedure requiring prolonged immobilization.",
"   </p>",
"   <p>",
"    Operative procedures for specific complications of burns to the hands and secondary reconstruction techniques are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15882?source=see_link&amp;anchor=H17954407#H17954407\">",
"     \"Principles of burn reconstruction: Extremities and regional nodal basins\", section on 'Hand'",
"    </a>",
"    .) Common techniques used in the management of burn hand deformities include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Z-Plasty &mdash; Z-plasty provides a method of scar lengthening and is particularly well suited for isolated scar bands and web space contractures where there is not a significant skin deficit. For large areas, multiple Z-plasty can be performed to lengthen the scar. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11446?source=see_link\">",
"       \"Z-plasty\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      V-Y plasty &mdash; This technique can be used to lengthen a scar or close a small defect. It is designed in line with the contracture in the shape of a \"V\". The \"V\" is then advanced and closed to form a \"Y\".",
"     </li>",
"     <li>",
"      Y-V plasty &mdash; Y-V plasties also provide a method of scar lengthening and are particularly useful for long linear scars. Y-V plasties do not require wide flap undermining as in the case of Z-plasties, since the flaps are advancement flaps and not transposition flaps. This is of particular importance when the flaps include scar tissue, since undermining of the Z-limbs in these situations may result in flap tip necrosis.",
"     </li>",
"     <li>",
"      Full thickness skin grafts &mdash; In cases of skin deficiency, Z-, V-Y, and Y-V plasties insufficiently address the scar defect. Skin grafts or flaps are needed in these cases. Digit and palm flexion contracture releases should be performed sharply under tourniquet control. Templates of the resulting defects should be obtained and full thickness skin grafts should be used to close these defects. In the case of digit contractures, temporary fixation of the digits (three to four weeks) with Kirschner wires can be used to maintain adequate digit positioning.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of a hand results in an overall 57 percent loss of independent function, hence aggressive measures to preserve function is a key component of burn management [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. A retrospective review of 1047 acutely burned hands (659 patients) described a return to normal function in 97 percent of patients with superficial burns and 81 percent with deep dermal or full-thickness burns [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/64\">",
"     64",
"    </a>",
"    ]. Only 9 percent of patients with burns involving bone or joint capsules regained normal function, but 90 percent were able to perform activities of daily living independently.",
"   </p>",
"   <p>",
"    The best measures to assess hand function and outcomes have not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18409/abstract/65\">",
"     65",
"    </a>",
"    ]. While it is possible to take many objective measures of hand movement, it can be difficult to correlate these with function, patient impairment, or quality of life. Future work in this area may help to improve outcome for the relatively small number of patients that have significant impairment following injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective treatment of hand burns requires a multifaceted and interdisciplinary approach.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mechanism of injury and the circumstances surrounding the injury may provide insight into the potential depth of injury. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Initial evaluation and management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adequate perfusion of the burned hand is determined by detecting radial and ulnar pulses by palpation or Doppler, determining capillary refill time, and monitoring oxygen saturation, compartment pressures, and temperature. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Initial evaluation and management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Escharotomies are indicated when clinical signs indicate poor perfusion or nerve entrapment. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Secondary management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fasciotomies are indicated when escharotomies fail to restore normal perfusion or release of neural pressure. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Secondary management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tissue flaps are used as coverage for exposed bones, joints, and tendons. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Secondary management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin grafts or tissue flap coverage are generally used within 14 to 21 days following injury to reduce the risk of functionally debilitating scars. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Tissue loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical therapy is started within 24 hours of the burn injury. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Post-operative care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Scarring and contractures are managed by physical therapy and operative correction to restore hand function. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/1\">",
"      Luce EA. The acute and subacute management of the burned hand. Clin Plast Surg 2000; 27:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/2\">",
"      Orgill DP, Piccolo N. Escharotomy and decompressive therapies in burns. J Burn Care Res 2009; 30:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/3\">",
"      Bardakjian VB, Kenney JG, Edgerton MT, Morgan RF. Pulse oximetry for vascular monitoring in burned upper extremities. J Burn Care Rehabil 1988; 9:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/4\">",
"      Piccolo NS, Piccolo MS, Piccolo PD, et al. Escharotomies, fasciotomies and carpal tunnel release in burn patients--review of the literature and presentation of an algorithm for surgical decision making. Handchir Mikrochir Plast Chir 2007; 39:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/5\">",
"      Lima AP, Beelen P, Bakker J. Use of a peripheral perfusion index derived from the pulse oximetry signal as a noninvasive indicator of perfusion. Crit Care Med 2002; 30:1210.",
"     </a>",
"    </li>",
"    <li>",
"     Wheeless, CR. Compartment syndromes of the hand and forearm. In: Wheeless' Textbook of Orthopaedics. www.wheelessonline.com/ortho/compartment_syndromes_of_hand_and_forearm (Accessed on June 18, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/7\">",
"      Kamolz LP, Kitzinger HB, Karle B, Frey M. The treatment of hand burns. Burns 2009; 35:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/8\">",
"      Kowalske KJ, Greenhalgh DG, Ward SR. Hand burns. J Burn Care Res 2007; 28:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/9\">",
"      Arnoldo B, Klein M, Gibran NS. Practice guidelines for the management of electrical injuries. J Burn Care Res 2006; 27:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/10\">",
"      Smith MA, Munster AM, Spence RJ. Burns of the hand and upper limb--a review. Burns 1998; 24:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/11\">",
"      Burd A, Noronha FV, Ahmed K, et al. Decompression not escharotomy in acute burns. Burns 2006; 32:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/12\">",
"      Salisbury RE, Taylor JW, Levine NS. Evaluation of digital escharotomy in burned hands. Plast Reconstr Surg 1976; 58:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/13\">",
"      Tiwari A, Haq AI, Myint F, Hamilton G. Acute compartment syndromes. Br J Surg 2002; 89:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/14\">",
"      Mann R, Gibran N, Engrav L, Heimbach D. Is immediate decompression of high voltage electrical injuries to the upper extremity always necessary? J Trauma 1996; 40:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/15\">",
"      Goodwin CW, Maguire MS, McManus WF, Pruitt BA Jr. Prospective study of burn wound excision of the hands. J Trauma 1983; 23:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/16\">",
"      Tambuscio A, Governa M, Caputo G, Barisoni D. Deep burn of the hands: Early surgical treatment avoids the need for late revisions? Burns 2006; 32:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/17\">",
"      van Zuijlen PP, Kreis RW, Vloemans AF, et al. The prognostic factors regarding long-term functional outcome of full-thickness hand burns. Burns 1999; 25:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/18\">",
"      Edstrom LE, Robson MC, Macchiaverna JR, Scala AD. Prospective randomized treatments for burned hands: nonoperative vs. operative. Preliminary report. Scand J Plast Reconstr Surg 1979; 13:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/19\">",
"      Engrav LH, Heimbach DM, Reus JL, et al. Early excision and grafting vs. nonoperative treatment of burns of indeterminant depth: a randomized prospective study. J Trauma 1983; 23:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/20\">",
"      Mohammadi AA, Bakhshaeekia AR, Marzban S, et al. Early excision and skin grafting versus delayed skin grafting in deep hand burns (a randomised clinical controlled trial). Burns 2011; 37:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/21\">",
"      Scott JR, Costa BA, Gibran NS, et al. Pediatric palm contact burns: a ten-year review. J Burn Care Res 2008; 29:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/22\">",
"      Barillo DJ, Arabitg R, Cancio LC, Goodwin CW. Distant pedicle flaps for soft tissue coverage of severely burned hands: an old idea revisited. Burns 2001; 27:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/23\">",
"      Hansen AJ, Duncan SF, Smith AA, et al. Reverse radial forearm fascial flap with radial artery preservation. Hand (N Y) 2007; 2:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/24\">",
"      Chang TS, Wang W, Guan WX, Hwang WY. The evolution of the free forearm flap. European Journal of Plastic Surgery 1989; 12:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/25\">",
"      Mago V. Retrograde posterior interosseous flap. Iowa Orthop J 2007; 27:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/26\">",
"      Dogra B, Singh M, Chakravarty B, Basu S. Posterior interosseous artery flap for hand defects. Armed Forces Med J India 2006; 62:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/27\">",
"      Kim KS. Distally based dorsal forearm fasciosubcutaneous flap. Plast Reconstr Surg 2004; 114:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/28\">",
"      Herter F, Ninkovic M, Ninkovic M. Rational flap selection and timing for coverage of complex upper extremity trauma. J Plast Reconstr Aesthet Surg 2007; 60:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/29\">",
"      Fuzaylov G, Fidkowski CW. Anesthetic considerations for major burn injury in pediatric patients. Paediatr Anaesth 2009; 19:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/30\">",
"      Latenser BA. Critical care of the burn patient: the first 48 hours. Crit Care Med 2009; 37:2819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/31\">",
"      Klein MB, Hunter S, Heimbach DM, et al. The Versajet water dissector: a new tool for tangential excision. J Burn Care Rehabil 2005; 26:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/32\">",
"      Rennekampff HO, Schaller HE, Wisser D, Tenenhaus M. Debridement of burn wounds with a water jet surgical tool. Burns 2006; 32:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/33\">",
"      Chandrasegaram MD, Harvey J. Full-thickness vs split-skin grafting in pediatric hand burns--a 10-year review of 174 cases. J Burn Care Res 2009; 30:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/34\">",
"      Schwanholt C, Greenhalgh DG, Warden GD. A comparison of full-thickness versus split-thickness autografts for the coverage of deep palm burns in the very young pediatric patient. J Burn Care Rehabil 1993; 14:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/35\">",
"      Heimbach DM, Warden GD, Luterman A, et al. Multicenter postapproval clinical trial of Integra dermal regeneration template for burn treatment. J Burn Care Rehabil 2003; 24:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/36\">",
"      Lattari V, Jones LM, Varcelotti JR, et al. The use of a permanent dermal allograft in full-thickness burns of the hand and foot: a report of three cases. J Burn Care Rehabil 1997; 18:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/37\">",
"      Wainwright D, Madden M, Luterman A, et al. Clinical evaluation of an acellular allograft dermal matrix in full-thickness burns. J Burn Care Rehabil 1996; 17:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/38\">",
"      Callcut RA, Schurr MJ, Sloan M, Faucher LD. Clinical experience with Alloderm: a one-staged composite dermal/epidermal replacement utilizing processed cadaver dermis and thin autografts. Burns 2006; 32:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/39\">",
"      Haslik W, Kamolz LP, Nathschl&auml;ger G, et al. First experiences with the collagen-elastin matrix Matriderm as a dermal substitute in severe burn injuries of the hand. Burns 2007; 33:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/40\">",
"      Jarvis MA, Jarvis CL, Jones PR, Spyt TJ. Reliability of Allen's test in selection of patients for radial artery harvest. Ann Thorac Surg 2000; 70:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/41\">",
"      Agir H, Sen C, Alag&ouml;z S, et al. Distally based posterior interosseous flap: primary role in soft-tissue reconstruction of the hand. Ann Plast Surg 2007; 59:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/42\">",
"      Mothes H, D&ouml;nicke T, Friedel R, et al. Indocyanine-green fluorescence video angiography used clinically to evaluate tissue perfusion in microsurgery. J Trauma 2004; 57:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/43\">",
"      Matsumura H, Engrav LH, Nakamura DY, Vedder NB. The use of the Millard \"crane\" flap for deep hand burns with exposed tendons and joints. J Burn Care Rehabil 1999; 20:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/44\">",
"      Baumeister S, K&ouml;ller M, Dragu A, et al. Principles of microvascular reconstruction in burn and electrical burn injuries. Burns 2005; 31:92.",
"     </a>",
"    </li>",
"    <li>",
"     Nugent, N, Mlakar, et al. Reconstruction of the burned hand. In: Total Burn Care, 3rd edition, Herndon, DN (Eds), Saunders Elsevier, Philadelphia 2007. p.687.",
"    </li>",
"    <li>",
"     Greenwood, JE, Clausen, J, Kavanagh, S. Experience wiht biobrane: Uses and caveats for success. ePlasty 2009 www.eplasty.com (Accessed on June 16, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/47\">",
"      Rajayogeswaran B, Bhatti AF, Giblin AV, Estela C. Treatment of hand scalds in the paediatric age group: a novel Biobrane glove. Burns 2008; 34:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/48\">",
"      Whitaker IS, Worthington S, Jivan S, Phipps A. The use of Biobrane by burn units in the United Kingdom: a national study. Burns 2007; 33:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/49\">",
"      Antony S, Terrazas S. A retrospective study: clinical experience using vacuum-assisted closure in the treatment of wounds. J Natl Med Assoc 2004; 96:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/50\">",
"      Venturi ML, Attinger CE, Mesbahi AN, et al. Mechanisms and clinical applications of the vacuum-assisted closure (VAC) Device: a review. Am J Clin Dermatol 2005; 6:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/51\">",
"      Weinand C. The Vacuum-Assisted Closure (VAC) device for hastened attachment of a superficial inferior-epigastric flap to third-degree burns on hand and fingers. J Burn Care Res 2009; 30:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/52\">",
"      Blackburn JH 2nd, Boemi L, Hall WW, et al. Negative-pressure dressings as a bolster for skin grafts. Ann Plast Surg 1998; 40:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/53\">",
"      Moisidis E, Heath T, Boorer C, et al. A prospective, blinded, randomized, controlled clinical trial of topical negative pressure use in skin grafting. Plast Reconstr Surg 2004; 114:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/54\">",
"      Landau AG, Hudson DA, Adams K, et al. Full-thickness skin grafts: maximizing graft take using negative pressure dressings to prepare the graft bed. Ann Plast Surg 2008; 60:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/55\">",
"      Kasukurthi R, Borschel GH. Simplified negative pressure wound therapy in pediatric hand wounds. Hand (N Y) 2010; 5:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/56\">",
"      Uygur F, Duman H, Ulk&uuml;r E, Ceik&ouml;z B. The role of the vacuum-assisted closure therapy in the salvage of venous congestion of the free flap: case report. Int Wound J 2008; 5:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/57\">",
"      Schrank C, Mayr M, Overesch M, et al. [Results of vacuum therapy (v.a.C.) of superficial and deep dermal burns]. Zentralbl Chir 2004; 129 Suppl 1:S59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/58\">",
"      Moore ML, Dewey WS, Richard RL. Rehabilitation of the burned hand. Hand Clin 2009; 25:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/59\">",
"      Lowell M, Pirc P, Ward RS, et al. Effect of 3M Coban Self-Adherent Wraps on edema and function of the burned hand: a case study. J Burn Care Rehabil 2003; 24:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/60\">",
"      Burm JS, Chung CH, Oh SJ. Fist position for skin grafting on the dorsal hand: I. Analysis of length of the dorsal hand surgery in hand positions. Plast Reconstr Surg 1999; 104:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/61\">",
"      Mann R, Yeong EK, Moore M, et al. Do custom-fitted pressure garments provide adequate pressure? J Burn Care Rehabil 1997; 18:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/62\">",
"      McCauley RL. Reconstruction of the pediatric burned hand. Hand Clin 2009; 25:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/63\">",
"      Anzarut A, Chen M, Shankowsky H, Tredget EE. Quality-of-life and outcome predictors following massive burn injury. Plast Reconstr Surg 2005; 116:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/64\">",
"      Sheridan RL, Hurley J, Smith MA, et al. The acutely burned hand: management and outcome based on a ten-year experience with 1047 acute hand burns. J Trauma 1995; 38:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18409/abstract/65\">",
"      Kowalske K. Outcome assessment after hand burns. Hand Clin 2009; 25:557.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 825 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.181.191-2D925142A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_62_18409=[""].join("\n");
var outline_f17_62_18409=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SECONDARY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neurovascular compromise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Escharotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Fasciotomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Peripheral nerve release",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Amputation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Tissue loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Excision and skin grafting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Tissue flaps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SURGICAL ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SURGICAL PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Escharotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Fasciotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Excision and grafting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Dermal regeneration templates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Tissue Flaps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Biobrane&trade; glove",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Vacuum assisted closure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      POST-OPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Physical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Edema management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Positioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Scarring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Contracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/825\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/825|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/4/32840\" title=\"figure 1\">",
"      Hand and wrist anatomy palmar view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/59/13236\" title=\"figure 2\">",
"      Burn hand anat dig",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/40/42625\" title=\"figure 3\">",
"      Burn hand eschr dig",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/825|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/45/30419\" title=\"picture 1\">",
"      Escharotomies dorsal hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/54/17252\" title=\"picture 2\">",
"      Excision and debridement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/37/11863\" title=\"picture 3\">",
"      Forearm fascia flap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/63/17395\" title=\"picture 4\">",
"      Pedicle advancement ab flap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/7/33908\" title=\"picture 5\">",
"      Contracture of burned hand",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4326?source=related_link\">",
"      Classification of burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=related_link\">",
"      Hypermetabolic response to severe burn injury: Recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29225?source=related_link\">",
"      Local treatment of burns: Topical antimicrobial agents and dressings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=related_link\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15882?source=related_link\">",
"      Principles of burn reconstruction: Extremities and regional nodal basins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32822?source=related_link\">",
"      Surgery for carpal tunnel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37479?source=related_link\">",
"      Treatment of minor thermal burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11446?source=related_link\">",
"      Z-plasty",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_62_18410="Peripartum cardiomyopathy";
var content_f17_62_18410=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Peripartum cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/62/18410/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/62/18410/contributors\">",
"     Wendy Tsang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/62/18410/contributors\">",
"     Amy C Bales, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/62/18410/contributors\">",
"     Roberto M Lang, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/62/18410/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/62/18410/contributors\">",
"     Candice Silversides, MD, MS, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/62/18410/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/62/18410/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/62/18410/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 17, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripartum cardiomyopathy (PPCM, also called pregnancy-associated cardiomyopathy) is a rare cause of heart failure (HF) that affects women late in pregnancy or in the early puerperium. Although initially described in 1849 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/1\">",
"     1",
"    </a>",
"    ], it was not recognized as a distinct clinical entity until the 1930s [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/2\">",
"     2",
"    </a>",
"    ]. Earlier terms for this condition include toxic postpartum heart failure, Meadows&rsquo; syndrome, Zaria syndrome, and postpartum myocardiosis.",
"   </p>",
"   <p>",
"    PPCM is a disorder of unknown etiology that has potentially devastating consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/3\">",
"     3",
"    </a>",
"    ]. Treatment is similar to that employed for other types of HF with left ventricular (LV) systolic dysfunction. However, modifications to standard therapy are often necessary to ensure the safety of the mother and the unborn or breastfeeding child. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of heart failure in pregnancy\", section on 'Medical management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    General discussions of critical illness during pregnancy and the peripartum period, of HF during pregnancy, and of issues related to pregnancy in women with acquired or congenital heart disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34681?source=see_link\">",
"     \"Critical illness during pregnancy and the peripartum period\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=see_link\">",
"     \"Management of heart failure in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=see_link\">",
"     \"Acquired heart disease and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link\">",
"     \"Pregnancy in women with congenital heart disease: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripartum cardiomyopathy is defined as a condition meeting four criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Development of heart failure (HF) in the last month of pregnancy or within five months of delivery.",
"     </li>",
"     <li>",
"      Absence of another identifiable cause for the HF. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=see_link\">",
"       \"Causes of dilated cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Absence of recognizable heart disease prior to the last month of pregnancy.",
"     </li>",
"     <li>",
"      LV systolic dysfunction (eg, left ventricular ejection fraction [LVEF] below 45 percent or a reduced fractional shortening).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Time of onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who develop cardiomyopathy earlier in pregnancy do not meet the definition of PPCM based upon the first and third criteria; however, the disease process is probably the same. The term pregnancy-associated cardiomyopathy (PACM, also known as early pregnancy-associated cardiomyopathy) has been used to describe this condition. The characteristics of early-onset disease were evaluated in a review of 123 women with a history of cardiomyopathy diagnosed during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/7\">",
"     7",
"    </a>",
"    ]. One-hundred women met the traditional criteria for PPCM, presenting at a mean of 38 weeks, and 23 presented earlier at a mean of 32 weeks. There were no differences between the two groups in terms of age, race, associated conditions, LVEF (29 versus 27 percent), the rate and time of recovery, and maternal outcomes. These observations suggest that patients with an early presentation may be part of the spectrum of PPCM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of PPCM varies. Much of the reported discrepancy is due to wide geographical variation, with reported incidences of 1:2289 to 1:4000 live births in the United States, 1:1000 in South Africa, 1:300 in Haiti, and 1:100 in Zaria, Nigeria [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/5,8-14\">",
"     5,8-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The wide range in reported incidence may reflect an overestimation in studies that rely solely on clinical criteria to make the diagnosis (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Diagnosis'",
"    </a>",
"    below). In addition, the high incidence in Nigeria may be related to a local Hausa custom of eating kanwa, a dry lake salt for forty days after delivery. It has been suggested that the development of PPCM in these patients may be related in part to hypervolemia and possibly hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/12,15,16\">",
"     12,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite many attempts to uncover a distinct etiology of PPCM, the cause still remains unknown and may be multifactional. No distinct hormonal disorder has been identified in patients with PPCM, even though estrogen, progesterone, and prolactin have significant effects on the cardiovascular system [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. A number of other factors have been evaluated and may contribute.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Inflammatory cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory cytokines may play a role in the pathogenesis and progression of cardiomyopathy and HF. The cytokines that are elevated in PPCM compared to controls include tumor necrosis factor (TNF)-alpha and interleukin-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In addition,",
"    <span class=\"nowrap\">",
"     Fas/Apo-1,",
"    </span>",
"    an apoptosis signaling receptor, and C-reactive protein are associated with more severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12872?source=see_link\">",
"     \"Nitric oxide, other hormones, cytokines, and chemokines in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of investigators have suggested myocarditis as a possible cause of PPCM [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/23-27\">",
"     23-27",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study evaluated 11 African women in Nairobi who presented with the clinical features of PPCM [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/24\">",
"       24",
"      </a>",
"      ]. Endomyocardial biopsies in five patients were consistent with a \"healing\" myocarditis, as evidenced by the presence of a mild inflammatory cell infiltration within the myocardium, with foci of necrosis and variable amounts of hypertrophy and fibrosis. Of the nine patients with at least six months follow-up, three of four with myocarditis had persistent HF, while four of five with no or sparse evidence of myocarditis had improvement in heart failure symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      left ventricular size and function.",
"     </li>",
"     <li>",
"      In two other series, myocarditis was present in 4 of 14 and 14 of 18 patients with PPCM, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. In comparison, myocarditis was present in only 5 of 55 patients (9 percent) in a comparator group with an idiopathic cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 26 patients with PPCM who had evidence of interstitial inflammation, viral genomes were noted in eight (31 percent). Viral genomes have also been noted in other forms of myocarditis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=see_link&amp;anchor=H3#H3\">",
"       \"Etiology and pathogenesis of myocarditis\", section on 'Viral or \"idiopathic\" myocarditis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a nonrandomized study, three patients with peripartum cardiomyopathy and myocarditis were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      and showed clinical improvement with no inflammatory infiltrate on repeat biopsy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, a retrospective review of endomyocardial biopsy specimens from 34 patients fulfilling the clinical criteria for a diagnosis of PPCM found a lower incidence of myocarditis (9 percent) than that reported in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/28\">",
"     28",
"    </a>",
"    ]. This incidence was comparable to that found in an age- and sex-matched control population undergoing transplantation for idiopathic dilated cardiomyopathy (9.1 percent).",
"   </p>",
"   <p>",
"    The reason for the discrepancy among the various studies is unclear. In addition to small sample size, the time of biopsy in relation to the onset of symptoms may also be important, since the incidence of inflammation is greater in patients who are biopsied soon after presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/26,28\">",
"     26,28",
"    </a>",
"    ]. Other potential reasons for the variability of the prevalence of myocarditis include: the inclusion of patients outside the accepted time frame of PPCM; variability among patient populations; and limitations of endomyocardial biopsy as a means of diagnosis myocarditis. These limitations include sampling error (since myocardial involvement may be patchy) and variability in histologic criteria for myocarditis (ie, whether patients with borderline myocarditis were included together with those with active myocarditis as defined by the Dallas criteria) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Abnormal immune response",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been suggested that a maternal immunologic response to a fetal antigen can lead to PPCM. Fetal cells may escape into the maternal circulation and remain there without being rejected due to weak immunogenicity of the paternal haplotype of the chimeric cells [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/29\">",
"     29",
"    </a>",
"    ]. If these cells lodge in the cardiac tissue, they can trigger a pathologic autoimmune response [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High titers of autoantibodies compared to controls have been described against normal human cardiac tissue proteins (including myosin), adenine nucleotide translocator, and branched chain alpha ketoacid dehydrogenase [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/5,30\">",
"     5,30",
"    </a>",
"    ]. In addition, the immunoglobulins in patients with PPCM may be significantly different in frequency and reactivity to those in dilated cardiomyopathy cohorts and healthy donors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/27\">",
"     27",
"    </a>",
"    ]. In contrast to these findings, a study of humoral immunity in 39 Nigerian women with PPCM found no difference compared to controls in the levels of serum immunoglobulins, circulating immune complexes, or cardiac muscle antibodies between subjects and controls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, the available data are insufficient to establish whether abnormal maternal immunological response is the cause of PPCM. The observed autoantibodies may be secondary epiphenomena or contribute directly to myocyte injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Familial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial clustering of PPCM has been observed in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/32\">",
"     32",
"    </a>",
"    ] and was more systematically evaluated in the following two studies, which included pedigree construction:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A study of patients evaluated at the University Medical Centre Groningen&rsquo;s cardiogenetics clinic found that PPCM occurred in five (6 percent) of 90 families with dilated cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/33\">",
"       33",
"      </a>",
"      ]. The investigators separately screened the first-degree relatives of three patients with PPCM who did not show a full recovery at one year and found undiagnosed dilated cardiomyopathy in the relatives of all three patients. These observations suggest that a subset of patients with PPCM have a familial dilated cardiomyopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A study of 520 pedigrees in the Familial Dilated Cardiomyopathy Research Project database found 45 cases of PPCM or pregnancy-associated cardiomyopathy (PACM) among 4110 women [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/34\">",
"       34",
"      </a>",
"      ]. Evidence of familial clustering of dilated cardiomyopathy was noted in 23 of 42 unrelated cases. Genetic data was available in nineteen (13 familial, 6 sporadic) of the 42 cases and known DCM mutations were found in five cases of PPCM and one case of PACM.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both these studies support the hypothesis that PPCM may develop as a result of interaction between pregnancy related factors (eg, late pregnancy oxidative stress) and a susceptible genetic background. However further work is required to determine the generalizability of these findings and to further identify mutations associated with PPCM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hemodynamic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;During pregnancy, there is a significant increase in blood volume and cardiac output, which results in transient LV remodeling and hypertrophy. It is possible that there is an exaggerated decrease in LV systolic function in women who develop PPCM. The hemodynamic stress of gestational hypertension, which is more common in women with PPCM, may contribute to the development of HF [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11716524\">",
"    <span class=\"h2\">",
"     Role of prolactin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Altered prolactin processing is thought to be involved in the pathogenesis of PPCM. Mice with a knockout in the cardiac tissue-specific signal transduction and activator of transcription 3 (STAT3), develop PPCM [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/36\">",
"     36",
"    </a>",
"    ]. Reduction in STAT3 leads to increased cleavage of prolactin into an antiangiogenic and proapoptotic 16kDa isoform. Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    , an inhibitor of prolactin secretion, prevents the development of PPCM in these mice. &nbsp;",
"   </p>",
"   <p>",
"    Reduced cardiac STAT3 levels have also been observed in terminally failing hearts from PPCM patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/36\">",
"     36",
"    </a>",
"    ], but this is a nonspecific finding seen in end-stage dilated cardiomyopathy, generally [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/37\">",
"     37",
"    </a>",
"    ]. It is unknown whether STAT3 levels are reduced in PPCM at an earlier stage of disease. Preliminary results of studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    therapy in women with PPCM suggest that prolactin could be a key target in clinical PPCM. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Bromocriptine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the etiology of PPCM remains unclear, a number of factors have been associated with increased risk, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age greater than 30 years [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/2,4,7,8\">",
"       2,4,7,8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Multiparity",
"     </li>",
"     <li>",
"      African descent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pregnancy with multiple fetuses [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/7,39\">",
"       7,39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A history of preeclampsia, eclampsia, or postpartum hypertension",
"     </li>",
"     <li>",
"      Maternal cocaine abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Long-term (&gt;4 weeks) oral tocolytic therapy with beta adrenergic agonists such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are conflicting data as to whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/37/13907?source=see_link\">",
"     selenium",
"    </a>",
"    deficiency is [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/42,43\">",
"     42,43",
"    </a>",
"    ] or is not [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/44\">",
"     44",
"    </a>",
"    ] a risk factor for PPCM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;PPCM is rarely seen before 36 weeks of gestation, and affected patients usually present during the first four to five months postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/15,45\">",
"     15,45",
"    </a>",
"    ]. This is in contrast to pregnant women with underlying cardiac disease (eg, ischemic, valvular, or myopathic) who may develop symptoms of HF earlier, beginning in the second trimester of gestation, coincident with increases in the hemodynamic burden imposed by the gravid state [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=see_link\">",
"     \"Renal and urinary tract physiology in normal pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients most commonly complain of dyspnea; other frequent symptoms include cough, orthopnea, paroxysmal nocturnal dyspnea, and hemoptysis. Nonspecific fatigue, chest discomfort, or abdominal pain may confuse the initial evaluation due to the occurrence of similar symptoms during normal pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic and pulmonary emboli are more common in PPCM than in other types of cardiomyopathy, probably because the risk associated with cardiomyopathy is exacerbated by the hypercoagulable state induced by pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Anticoagulation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the diagnosis of PPCM has been based upon four clinical criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Development of cardiac failure in the last month of pregnancy or within five months of delivery.",
"     </li>",
"     <li>",
"      Absence of an identifiable cause for the cardiac failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=see_link\">",
"       \"Causes of dilated cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Absence of recognizable heart disease prior to the last month of pregnancy.",
"     </li>",
"     <li>",
"      LV systolic dysfunction (eg, LVEF &lt;45 percent or a reduced shortening fraction).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The last criterion was added to prevent the inclusion of patients with disorders that mimic systolic HF [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/6,13\">",
"     6,13",
"    </a>",
"    ]. Such disorders include accelerated hypertension, diastolic dysfunction, systemic infection, pulmonary embolism, or complications of late pregnancy itself (eg, preeclampsia or amniotic fluid embolus).",
"   </p>",
"   <p>",
"    An electrocardiogram (ECG) and echocardiogram should be performed in patients who are clinically suspected of having PPCM. Other studies such as brain natriuretic peptide (BNP) levels, cardiac catheterization, chest x-ray, endomyocardial biopsy, and viral serologies can be considered in selected cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECG findings include sinus tachycardia (or rarely, atrial fibrillation), nonspecific ST and T wave abnormalities, and voltage abnormalities (low voltage or criteria for left ventricular hypertrophy). Q waves are occasionally present in the anterior precordium. PR and QRS intervals may also be prolonged [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/4,9\">",
"     4,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The echocardiogram usually reveals a global reduction in contractility and LV enlargement without hypertrophy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60087 \" href=\"UTD.htm?41/34/42529\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/13\">",
"     13",
"    </a>",
"    ]. Doppler assessment of cardiac pressures can usually also be performed, making right heart catheterization unnecessary in most patients.",
"   </p>",
"   <p>",
"    The threshold of LV enlargement and dysfunction necessary to diagnose PPCM has not been precisely defined. The following definition, based upon a 1992 NHLBI workshop definition for idiopathic dilated cardiomyopathy, has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/6,47\">",
"     6,47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LVEF &lt;45 percent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fractional shortening &lt;30 percent",
"      <strong>",
"       PLUS",
"      </strong>",
"     </li>",
"     <li>",
"      LV end-systolic dimension greater than 2.7",
"      <span class=\"nowrap\">",
"       cm/m2",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although most cardiologists would consider a cardiomyopathy to be present if there is any reduction in the LVEF (&lt;50 percent), this would not meet the strict criterion for PPCM.",
"   </p>",
"   <p>",
"    Other possible echocardiographic findings include [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Regional heterogeneities of systolic wall thickening",
"     </li>",
"     <li>",
"      Left atrial enlargement",
"     </li>",
"     <li>",
"      Mitral and tricuspid regurgitation",
"     </li>",
"     <li>",
"      Small pericardial effusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84779155\">",
"    <span class=\"h2\">",
"     BNP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women presenting with PPCM typically have elevated brain natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) levels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/48\">",
"     48",
"    </a>",
"    ]. Measurement of BNP levels during pregnancy is discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=see_link&amp;anchor=H92292543#H92292543\">",
"     \"Acquired heart disease and pregnancy\", section on 'Measurement of BNP'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Chest x-ray",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest x-ray typically shows enlargement of the cardiac silhouette with evidence of pulmonary venous congestion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    interstitial edema, and, on occasion, pleural effusions. However, a chest x-ray is not necessary to make the diagnosis of PPCM, and exposes the patient to ionizing radiation (",
"    <a class=\"graphic graphic_table graphicRef50090 \" href=\"UTD.htm?4/60/5069\">",
"     table 1",
"    </a>",
"    ). If, despite a thorough physical examination, the diagnosis of pulmonary edema is uncertain and a chest x-ray is necessary to make that diagnosis, it can be considered and discussed with the patient. If a chest x-ray is performed, fetal shielding should be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link&amp;anchor=H14#H14\">",
"     \"Diagnostic imaging procedures during pregnancy\", section on 'Plain films'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11716565\">",
"    <span class=\"h2\">",
"     Cardiac magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been limited reports on the use of cardiac magnetic resonance (CMR) imaging in PPCM, and its role is still being evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/49-56\">",
"     49-56",
"    </a>",
"    ]. Case reports and small series have noted variable presence of late gadolinium enhancement (LGE) in patients with PPCM [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/51-56\">",
"     51-56",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link&amp;anchor=H36992798#H36992798\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Late gadolinium enhancement'",
"    </a>",
"    ). This variability likely reflects the diverse processes that lead to PPCM. Case reports suggest that the presence and persistence of LGE may be associated with poor recovery of cardiac function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/55\">",
"     55",
"    </a>",
"    ], improving LGE may be associated with cardiac recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/52\">",
"     52",
"    </a>",
"    ], while lack of LGE may be associated with presence or absence of cardiac recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/54\">",
"     54",
"    </a>",
"    ]. However the prognostic value of CMR in PPCM has not been established.",
"   </p>",
"   <p>",
"    Magnetic resonance imaging and gadolinium administration during pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link&amp;anchor=H26#H26\">",
"     \"Diagnostic imaging procedures during pregnancy\", section on 'Magnetic resonance imaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link&amp;anchor=H26949515#H26949515\">",
"     \"Diagnostic imaging procedures during pregnancy\", section on 'Gadolinium'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cardiac catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Right heart catheterization is rarely needed because assessment of cardiac pressures can usually be made with Doppler echocardiography. It may be helpful in critically ill patients who need more complete assessment or constant evaluation of their hemodynamic state.",
"   </p>",
"   <p>",
"    Left heart catheterization with coronary angiography is only indicated in selected patients with to evaluate coronary artery disease as a potential cause for the cardiomyopathy (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link&amp;anchor=H9#H9\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\", section on 'Indications for immediate angiography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\", section on 'Diagnosis'",
"    </a>",
"    ). Diagnostic coronary angiography exposes the patient to ionizing radiation (equivalent to ~ 100 or more chest x-rays) (",
"    <a class=\"graphic graphic_table graphicRef50090 \" href=\"UTD.htm?4/60/5069\">",
"     table 1",
"    </a>",
"    ), and therefore it is important to carefully consider the appropriate timing of testing, to discuss the risks of fluoroscopy with the patient and to employ fetal shielding if the procedure must be performed during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnostic imaging procedures during pregnancy\", section on 'Fluoroscopy and angiography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Endomyocardial biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of endomyocardial biopsy remains unclear. As noted above, a variable proportion of patients have evidence of myocarditis. Other histologic findings in PPCM can include myofiber hypertrophy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    degeneration, fibrosis, and interstitial edema [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/4,8\">",
"     4,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no pathognomonic findings in PPCM, and there is an inherent risk in performing a biopsy of a dilated right ventricle. The decision whether or not to perform an endomyocardial biopsy should be left to the discretion of the physician and patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7592?source=see_link\">",
"     \"Endomyocardial biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Viral and bacterial studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of viral and bacterial cultures, as well as selected viral titers (eg, Coxsackie B) is unclear. The results of these tests are nonspecific and they have limited prognostic value in patients with myocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=see_link&amp;anchor=H29#H29\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\", section on 'Determination of specific etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84779113\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PPCM is a diagnosis of exclusion. As noted in the 2010 European Society of Cardiology (ESC) working group statement on peripartum cardiomyopathy, the differential diagnosis includes pre-existing idiopathic dilated cardiomyopathy unmasked by pregnancy, pre-existing familial dilated cardiomyopathy unmasked by pregnancy,",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    cardiomyopathy, pre-existing valvular heart disease unmasked by pregnancy, hypertensive heart disease, pre-existing unrecognized congenital heart disease, pregnancy-associated myocardial infarction, and pulmonary embolus [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=see_link\">",
"     \"Acquired heart disease and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/21/35159?source=see_link\">",
"     \"Pregnancy in women with congenital heart disease: Specific lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of PPCM is largely similar to that for other types of heart failure (HF). Additional therapeutic issues include anticoagulation and arrhythmia management. Immunosuppression and immune globulin therapy have also been evaluated, although the role of these treatments in PPCM is not established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Heart failure treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with PPCM and HF, the goals of medical therapy are similar to those in patients with HF due to other causes. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Optimizing hemodynamics",
"     </li>",
"     <li>",
"      Relief of symptoms",
"     </li>",
"     <li>",
"      When possible, chronic therapies that improve long-term outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    General discussions of the treatment of acute and chronic HF are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the unique issues related to pregnancy and the peripartum period, however, each therapeutic decision has additional implications. The treatment of HF during pregnancy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of heart failure in pregnancy\", section on 'Medical management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the purposes of this discussion, the following is a brief summary of medical therapy of HF in pregnancy:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17112400\">",
"    <span class=\"h3\">",
"     Avoid angiotensin inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors and ARBs are contraindicated at any time in pregnancy due to a high risk of adverse fetal effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    .) ACE inhibitors have been safely used in women who are breast feeding. There are no data on ARB safety during breast feeding, and therefore we do not recommend using these medications during breast feeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17112407\">",
"    <span class=\"h3\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretics are given for symptomatic relief of pulmonary congestion and marked peripheral edema in pregnancy. A bleeding diathesis and hyponatremia have been reported in neonates of women who have taken thiazide diuretics during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of heart failure in pregnancy\", section on 'Diuretics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17112414\">",
"    <span class=\"h3\">",
"     Digoxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not a first-line therapy in most cases,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is appropriate for selected HF patients, and it can be particularly useful in PPCM for two reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of conventional HF therapies is limited during pregnancy, most notably due to the contraindication of angiotensin blockade with ACE inhibitors or ARBs.",
"     </li>",
"     <li>",
"      The increased physiologic demands of pregnancy can exacerbate HF symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    is generally safe in pregnancy, despite anecdotal reports of adverse effects. Small amounts of digoxin are secreted in breast milk, although no adverse effects have been reported in newborns. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of heart failure in pregnancy\", section on 'Digoxin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17112421\">",
"    <span class=\"h3\">",
"     Vasodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because ACE inhibitors and ARBs are contraindicated in pregnancy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    is the drug of choice when antepartum oral vasodilator therapy is necessary. It has been used for many years in the treatment of hypertension during pregnancy and appears to be safe for both the mother and fetus.",
"   </p>",
"   <p>",
"    When intravenous vasodilators are necessary in patients with severe decompensated HF, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    is favored. In selected cases,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/16/33029?source=see_link\">",
"     nesiritide",
"    </a>",
"    may be used, although due to potential toxicities to the fetus, these medications should only be used when all other interventions have failed and when it is essential for maternal well&ndash;being. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=see_link&amp;anchor=H14#H14\">",
"     \"Management of heart failure in pregnancy\", section on 'Vasodilators'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17112428\">",
"    <span class=\"h3\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers are generally safe during pregnancy, although adverse events have been reported. In general, agents that are beta-1 selective are preferable, since these agents are less likely to interfere with beta-2 mediated uterine relaxation and peripheral vasodilation. Infants born to mothers treated with these medications should be observed for side effects of beta blocker therapy including bradycardia and hypoglycemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=see_link&amp;anchor=H9#H9\">",
"     \"Management of heart failure in pregnancy\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Beta blockers can be used in women who are breast feeding.",
"   </p>",
"   <p>",
"    Beta blockers are not initiated during the acute phase of decompensated HF, but are an important component of the chronic treatment regimen for patients with HF due to systolic dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17112438\">",
"    <span class=\"h3\">",
"     Aldosterone antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic therapy with aldosterone antagonists",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    prolong survival in selected HF patients. However, there is neither data nor clinical experience to support the safety of these agents during pregnancy. Thus, we suggest that these agents not be used during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17112445\">",
"    <span class=\"h3\">",
"     Inotropes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with acute decompensated HF and hypotension benefit from intravenous inotropic support. Each of the inotropic medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    , dopamine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    ) has slightly different properties and pregnancy-related risks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=see_link&amp;anchor=H16#H16\">",
"     \"Management of heart failure in pregnancy\", section on 'Inotropes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=see_link\">",
"     \"Inotropic agents in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17112452\">",
"    <span class=\"h2\">",
"     Vasopressors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasopressors (eg, norepinephrine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    ) are usually avoided in patients with HF, because such patients usually have high systemic vascular resistance at baseline and further peripheral vasoconstriction may impair cardiac output. In pregnant women, vasopressors carry the additional risk of impairing uterine blood flow. In critically ill, hypotensive patients, however, blood pressure may need to be supported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34681?source=see_link&amp;anchor=H14#H14\">",
"     \"Critical illness during pregnancy and the peripartum period\", section on 'Vasopressors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Arrhythmia management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial fibrillation occurs occasionally in patients with PPCM [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/58\">",
"     58",
"    </a>",
"    ]. Sustained ventricular tachycardia has rarely been reported with PPCM. Management of arrhythmias during pregnancy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14362?source=see_link\">",
"     \"Supraventricular arrhythmias during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7674?source=see_link\">",
"     \"Ventricular arrhythmias during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PPCM are at high risk for thrombus formation and thromboembolism due to both the hypercoagulable state of pregnancy and stasis of blood due to severe LV dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/59\">",
"     59",
"    </a>",
"    ]. Thus, clinicians should consider the use of anticoagulants in these patients, particularly when the degree of LV dysfunction is severe (eg, LVEF &lt;30 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=see_link&amp;anchor=H19#H19\">",
"     \"Management of heart failure in pregnancy\", section on 'Anticoagulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=see_link\">",
"     \"Indications for antithrombotic therapy in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Choosing a specific anticoagulation regimen for a pregnant woman is challenging due to the potential teratogenic effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and dosing complexities of the various agents. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Immunosuppressive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive therapy has occasionally been initiated in patients with PPCM and biopsy-proven myocarditis, but its efficacy is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/26\">",
"     26",
"    </a>",
"    ]. Empiric immunosuppression, in the absence of evidence of myocarditis, is not recommended since most reported cases have nonspecific biopsy findings [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/13\">",
"     13",
"    </a>",
"    ]. These drugs often have significant side effects, and studies in other forms of myocarditis have not shown clear benefit from immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10874?source=see_link&amp;anchor=H14#H14\">",
"     \"Natural history and therapy of myocarditis in adults\", section on 'Immunosuppressive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immune globulin (IVIG) has been tried in patients with myocarditis or recent-onset dilated cardiomyopathy with no clear evidence of benefit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10874?source=see_link&amp;anchor=H15#H15\">",
"     \"Natural history and therapy of myocarditis in adults\", section on 'IVIG'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Its role in PPCM was evaluated in a retrospective study of six women treated with IVIG and 11 controls treated conventionally [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/61\">",
"     61",
"    </a>",
"    ]. After a six-month follow-up, the absolute increase in LVEF was greater in those treated with IVIG compared to controls (26 versus 13 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Bromocriptine",
"    </span>",
"    &nbsp;&mdash;&nbsp;This treatment strategy is based upon an experimental observation of prevention of PPCM in mice via prolactin blockade with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/36\">",
"     36",
"    </a>",
"    ]. A small randomized pilot study and several case reports have suggested a beneficial response to bromocriptine therapy in patients with PPCM [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. However available data are insufficient to recommend routine use of bromocriptine treatment for PPCM. Of note, the drug stops the production of breast milk making breastfeeding impossible.",
"   </p>",
"   <p>",
"    In a randomized open-label study performed in South Africa, 20 women with newly diagnosed PPCM were randomly assigned to receive either standard care plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    (2.5 mg twice daily for two weeks followed by 2.5 mg daily for 6 weeks) or standard care alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/62\">",
"     62",
"    </a>",
"    ]. The 10 women receiving bromocriptine demonstrated significantly greater improvement in left ventricular ejection fraction as compared to the 10 women receiving standard care only (27 to 58 percent versus 27 to 36 percent). One patient in the bromocriptine group died as compared to four in the standard care group. Fewer patients in the bromocriptine group reached the composite endpoint of death, NYHA functional class III or IV heart failure (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ), or left ventricular ejection fraction &lt;35 percent at six months as compared to patients in the standard care group (1 versus 8). The generalizability of these results is unclear given the small sample size, the higher than expected mortality rate in the standard care group, and differences in characteristics of PPCM in patients in Africa as compared to those elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This drug appears promising but there is insufficient evidence to establish the safety and efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    treatment for PPCM. &nbsp;Larger trials are needed. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Heart transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart transplantation is often the only acceptable treatment for women in whom more conventional therapy is not successful. Older studies found that transplantation was performed in up to one-third of women with PPCM [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/26,66,67\">",
"     26,66,67",
"    </a>",
"    ]. However, in more contemporary reports, transplantation was required in only 4 to 7 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/7,68\">",
"     7,68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=see_link\">",
"     \"Indications and contraindications for cardiac transplantation\"",
"    </a>",
"    .) Women with PPCM and significant left ventricular systolic dysfunction should be managed at a center with transplant capabilities. &nbsp;",
"   </p>",
"   <p>",
"    Success rates appear to be good, with a favorable long-term survival and frequency of transplant-associated complications comparable to that of age- and sex-matched controls with idiopathic dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/69\">",
"     69",
"    </a>",
"    ]. However some studies have found higher rates of rejection within the first six months after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aggressive life support measures such as ventricular assist devices should be used as a bridge to transplantation when more conservative actions are not adequate to sustain life as the patient awaits the arrival of a new heart. In a small study, four of six patients treated with mechanical assist devices for between 24 to 64 days survived [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/70\">",
"     70",
"    </a>",
"    ]. Of the two that died, one suffered a cerebral vascular accident twelve days after placement of a total artificial heart and the other died secondary to sepsis nearly a year after implantation of a total artificial heart. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=see_link\">",
"     \"Intermediate- and long-term mechanical cardiac support\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequent pregnancy has been cautiously undertaken with careful observation and management in women who have undergone successful heart transplantation for PPCM. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Subsequent pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84779209\">",
"    <span class=\"h1\">",
"     DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available to guide the timing and mode of delivery in PPCM. Decisions regarding timing and mode of delivery should be based on combined input from the cardiology, obstetrics, anesthesiology, and pediatric services. In this regard, multidisciplinary conferences are often useful.",
"   </p>",
"   <p>",
"    In women with PPCM with advanced heart failure, we suggest prompt delivery for maternal cardiovascular indications.",
"   </p>",
"   <p>",
"    For other women, the risks and benefits of early delivery should be considered and discussed with the patient. The 2010 ESC working group statement advised that early delivery is not required if the maternal and fetal conditions are stable [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/57\">",
"     57",
"    </a>",
"    ]. However, patient-specific issues, including gestational age, cervical status, and the potential cardiovascular impact of continuing pregnancy should be considered in timing delivery.",
"   </p>",
"   <p>",
"    As for women with other types of cardiac conditions, cesarean delivery is generally reserved for obstetrical indications (eg, failure of progression of labor, placenta previa, fetal intolerance of labor). In addition, cesarean delivery may be required for women who are critically ill and in need of inotropic therapy or mechanical support [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/35,57\">",
"     35,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84779281\">",
"    <span class=\"h1\">",
"     BREASTFEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although these is no clear data showing adverse cardiac effects from breast feeding by women with PPCM, many experts, including the 2010 ESC working group, suggest that breast feeding be avoided because of the potential effects of prolactin subfragments (see",
"    <a class=\"local\" href=\"#H11716524\">",
"     'Role of prolactin'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    If a decision is made to proceed with breastfeeding, we suggest avoiding angiotensin II receptor blockers due to lack of safety data (see",
"    <a class=\"local\" href=\"#H17112400\">",
"     'Avoid angiotensin inhibition'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of PPCM must take into account maternal, obstetric, and neonatal outcomes, and the effect of subsequent pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Maternal outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have evaluated the outcome of women with PPCM [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/7,21,68,71-75\">",
"     7,21,68,71-75",
"    </a>",
"    ]. The largest series of 123 cases of PPCM cited above (23 with onset more than one month before delivery) described a cardiac transplantation rate of 4 percent and a mortality rate of approximately 10 percent at a mean follow-up of about two years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/7\">",
"     7",
"    </a>",
"    ]. Similar findings were noted in two overlapping reports from Johns Hopkins: a mortality rate of 6 percent at five years (",
"    <a class=\"graphic graphic_figure graphicRef75646 \" href=\"UTD.htm?24/48/25358\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/71\">",
"     71",
"    </a>",
"    ] and a transplant rate of 7 percent at 8.6 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Heart transplantation'",
"    </a>",
"    above.) In comparison, higher mortality rates were noted in two other reports with a total of 57 patients in which there were 13 deaths (mortality 23 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/21,73\">",
"     21,73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Death due to PPCM is usually caused by progressive pump failure, sudden death, or thromboembolic events. The following adverse prognostic factors have been identified in different studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Worse New York Heart Association (NYHA) functional class (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Black women [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/21,35\">",
"       21,35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Multiparity [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among the patients who did not die or require transplantation in the study of 123 patients, the mean LVEF increased from 28 percent at diagnosis to 46 percent at a mean of about two years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/7\">",
"     7",
"    </a>",
"    ]. Recovery to an LVEF above 50 percent occurred in 54 percent of patients, and the degree of recovery was greatest in those with a baseline LVEF &gt;30 percent. An implantable cardioverter-defibrillator or permanent pacemaker was required in 3 and 2 percent of patients, respectively. In this and other studies, almost all of the recovery of LV function occurred by six months after diagnosis (",
"    <a class=\"graphic graphic_figure graphicRef75329 graphicRef54340 \" href=\"UTD.htm?34/57/35738\">",
"     figure 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/4,7,21\">",
"     4,7,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Different studies have identified the following predictors of persistent LV dysfunction at follow-up:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LVEF &le;30 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Fractional shortening less than 20 percent and a left ventricular end-diastolic dimension &ge;6 cm [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/76\">",
"       76",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Elevated cardiac troponin T [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A report of six women with a baseline LVEF of 25 percent demonstrated that the degree of contractile reserve as determined during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography (LVEF 54 percent) correlated with the LVEF at five-month follow-up (LVEF 53 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/78\">",
"     78",
"    </a>",
"    ]. Although stress echocardiography is being used by many clinicians to risk stratify women after their index pregnancy, this intriguing finding needs to be confirmed in other studies.",
"   </p>",
"   <p>",
"    While recovery of LV function in patients with PPCM is related to the degree of dysfunction at the time of diagnosis, baseline LVEF has limited sensitivity for prediction of improvement in individual patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/79\">",
"     79",
"    </a>",
"    ]. Thus, a severely depressed baseline LVEF should not be used as an indication for premature use of aggressive therapies such as ventricular assist devices and cardiac transplantation.",
"   </p>",
"   <p>",
"    PPCM is associated with significant extracardiac morbidity. In a study of 182 women, up to one-third of patients with transplantation-free survival had residual brain damage as a result of cerebrovascular accident or cardiopulmonary arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether women with PPCM have a different prognosis than pregnant women with other forms of cardiomyopathy is not clear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=see_link&amp;anchor=H14#H14\">",
"     \"Acquired heart disease and pregnancy\", section on 'Cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Obstetric and neonatal outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are more limited on obstetric and fetal outcomes. In the above report of 123 patients, cesarean delivery was performed in 40 percent of patients, largely for obstetric indications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/7\">",
"     7",
"    </a>",
"    ]. Preterm birth (&lt;37 weeks) occurred in 25 percent, the mean birth weight was 3.1 kg (range 1.4 to 5.0 kg), and 5.9 percent of infants were small for date. There were two stillbirths, one neonatal death, and four newborns had congenital anomalies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Subsequent pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risks associated with subsequent pregnancies in women with a history of PPCM are incompletely defined. The available data come from several small case series, which suggest that the risk of complications is high, particularly among women who do not have full recovery of LV function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Recovered LV function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among women in whom LV function returns to normal, the risk of subsequent pregnancy appears lower than for those with persistent LV dysfunction, but elevated compared to the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. In a series of 28 women who recovered to an LVEF &ge;50 percent after the initial episode, the following results in subsequent pregnancies were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/81\">",
"     81",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were no deaths.",
"     </li>",
"     <li>",
"      There was a reduction in the mean LVEF (56 to 49 percent), and the LVEF fell by more than 20 percent in six women (21 percent).",
"     </li>",
"     <li>",
"      Six patients developed HF symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The persistent risk in such women may be related to subtle residual dysfunction that is not detected on resting evaluations. Support for this hypothesis comes from a report of seven women with a history of PPCM who regained normal resting LV size and performance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/74\">",
"     74",
"    </a>",
"    ]. Contractile reserve, assessed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    challenge, was significantly impaired compared to matched controls.",
"   </p>",
"   <p>",
"    In summary, some women who recover LV function after an initial episode of PPCM will have significant decline in LV function during a subsequent pregnancy. These women should be counseled about the potential risks prior to pregnancy, and carefully monitored for signs of ventricular dysfunction if they choose to become pregnant again.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Persistent LV dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential risks of subsequent pregnancy in women who have persistent LV systolic dysfunction appear to be substantial, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of women with PPCM who had subsequent pregnancies, 16 women had persistent LV dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/81\">",
"       81",
"      </a>",
"      ]. Among these women three died (19 percent). In addition, there was a further reduction in the mean LVEF (36 to 32 percent), heart failure (HF) symptoms developed in seven patients, premature delivery in six, and therapeutic abortion in four.",
"     </li>",
"     <li>",
"      In a report of six women who had subsequent pregnancies after PPCM, two who had persistent LV dysfunction died three months postpartum due to HF [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A more complex pattern was illustrated in a review of 15 women with PPCM, 14 of whom had incomplete LV recovery [",
"      <a class=\"abstract\" href=\"UTD.htm?17/62/18410/abstract/84\">",
"       84",
"      </a>",
"      ]. Subsequent pregnancy resulted in worsening HF in eight women (53 percent) and one death from worsening HF 10 months postpartum. Seven women did not develop worsening HF during the second pregnancy; these women all had continued improvement and normalization of LV function (LVEF &ge;50 percent) within 30 months of the subsequent pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, although some women tolerate further pregnancies, those with persistent LV dysfunction should be advised to",
"    <strong>",
"     avoid pregnancy",
"    </strong>",
"    due to the risk of HF progression and death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Following heart transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only anecdotal reports of successful pregnancy in patients who have undergone heart transplantation for PPCM. In addition to the problems related to pregnancy after heart transplantation for any reason, women who have been transplanted for PPCM may be at risk for graft failure due to recurrent disease. These women should be strongly advised to",
"    <strong>",
"     avoid",
"    </strong>",
"    future pregnancy until further data are collected.",
"   </p>",
"   <p>",
"    The risks of subsequent pregnancy in women who have undergone heart transplantation for reasons other than PPCM are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20487?source=see_link\">",
"     \"Pregnancy after cardiac transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PPCM is a rare disorder of unknown etiology with potentially devastating consequences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     General issues",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PPCM is defined by the development of a reduced LVEF in the last month of pregnancy or within five months of delivery, in the absence of an identifiable cause for the cardiac failure or recognizable heart disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The reported incidence of PPCM varies widely across geographic regions (from 1:15,000 to 1:100 deliveries). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology of PPCM is unknown, with possible causes including genetic, inflammatory, and autoimmune factors. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of risk factors for PPCM have been identified, including age, multiparity, African descent, and a history of preeclampsia, eclampsia, or postpartum hypertension. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of HF due to PPCM is similar to that of HF due to other causes that occur during pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=see_link&amp;anchor=H7#H7\">",
"       \"Management of heart failure in pregnancy\", section on 'Medical management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that immunosuppressive agents not be administered routinely for the treatment of PPCM (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Immunosuppressive agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that intravenous immune globulin not be administered routinely for the treatment of PPCM (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Intravenous immune globulin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that women with a history of PPCM who have persistent LV dysfunction should be advised to",
"      <strong>",
"       avoid pregnancy",
"      </strong>",
"      due to the risk of HF progression and death (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Persistent LV dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/1\">",
"      Richie, C. Clinical contribution to the pathology, diagnosis and treatment of certain chronic diseases of the heart. Edinb Med Surg J 1849; 2:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/2\">",
"      Hull, E, Hafkesbring, E. \"Toxic\" postpartal heart disease. New Orleans Med Surg J 1937; 89:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/3\">",
"      Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet 2006; 368:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/4\">",
"      Demakis JG, Rahimtoola SH, Sutton GC, et al. Natural course of peripartum cardiomyopathy. Circulation 1971; 44:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/5\">",
"      Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 2000; 283:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/6\">",
"      Hibbard JU, Lindheimer M, Lang RM. A modified definition for peripartum cardiomyopathy and prognosis based on echocardiography. Obstet Gynecol 1999; 94:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/7\">",
"      Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation 2005; 111:2050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/8\">",
"      SEFTEL H, SUSSER M. Maternity and myocardial failure in African women. Br Heart J 1961; 23:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/9\">",
"      Davidson NM, Parry EH. The etiology of peripartum cardiac failure. Am Heart J 1979; 97:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/10\">",
"      WOOLFORD RM. Postpartum myocardosis. Ohio Med 1952; 48:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/11\">",
"      PIERCE JA, PRICE BO, JOYCE JW. Familial occurrence of postpartal heart failure. Arch Intern Med 1963; 111:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/12\">",
"      Sliwa K, Damasceno A, Mayosi BM. Epidemiology and etiology of cardiomyopathy in Africa. Circulation 2005; 112:3577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/13\">",
"      Lampert MB, Lang RM. Peripartum cardiomyopathy. Am Heart J 1995; 130:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/14\">",
"      Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc 2005; 80:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/15\">",
"      Sanderson JE, Adesanya CO, Anjorin FI, Parry EH. Postpartum cardiac failure--heart failure due to volume overload? Am Heart J 1979; 97:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/16\">",
"      Fillmore SJ, Parry EH. The evolution of peripartal heart failure in Zaria, Nigeria. Some etiologic factors. Circulation 1977; 56:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/17\">",
"      KING TM, WHITEHORN WV, REEVES B, KUBOTA R. Effects of estrogen on composition and function of cardiac muscle. Am J Physiol 1959; 196:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/18\">",
"      Ueland K, Parer JT. Effects of estrogens on the cardiovascular system of the ewe. Am J Obstet Gynecol 1966; 96:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/19\">",
"      Schaible TF, Malhotra A, Ciambrone G, Scheuer J. The effects of gonadectomy on left ventricular function and cardiac contractile proteins in male and female rats. Circ Res 1984; 54:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/20\">",
"      Bryant EE, Douglas BH, Ashburn AD. Circulatory changes following prolactin administration. Am J Obstet Gynecol 1973; 115:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/21\">",
"      Sliwa K, Skudicky D, Bergemann A, et al. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol 2000; 35:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/22\">",
"      Sliwa K, F&ouml;rster O, Libhaber E, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J 2006; 27:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/23\">",
"      Melvin KR, Richardson PJ, Olsen EG, et al. Peripartum cardiomyopathy due to myocarditis. N Engl J Med 1982; 307:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/24\">",
"      Sanderson, JE, Olsen, EG, Gatei, D. Peripartum heart disease: An endomyocardial biopsy study. Br Heart J 1986; 56:285. 1986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/25\">",
"      O'Connell JB, Costanzo-Nordin MR, Subramanian R, et al. Peripartum cardiomyopathy: clinical, hemodynamic, histologic and prognostic characteristics. J Am Coll Cardiol 1986; 8:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/26\">",
"      Midei MG, DeMent SH, Feldman AM, et al. Peripartum myocarditis and cardiomyopathy. Circulation 1990; 81:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/27\">",
"      B&uuml;ltmann BD, Klingel K, N&auml;bauer M, et al. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gynecol 2005; 193:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/28\">",
"      Rizeq MN, Rickenbacher PR, Fowler MB, Billingham ME. Incidence of myocarditis in peripartum cardiomyopathy. Am J Cardiol 1994; 74:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/29\">",
"      Nelson JL. Pregnancy, persistent microchimerism, and autoimmune disease. J Am Med Womens Assoc 1998; 53:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/30\">",
"      Ansari AA, Fett JD, Carraway RE, et al. Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clin Rev Allergy Immunol 2002; 23:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/31\">",
"      C&eacute;nac A, Beaufils H, Soumana I, et al. Absence of humoral autoimmunity in peripartum cardiomyopathy. A comparative study in Niger. Int J Cardiol 1990; 26:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/32\">",
"      Pearl W. Familial occurrence of peripartum cardiomyopathy. Am Heart J 1995; 129:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/33\">",
"      van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation 2010; 121:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/34\">",
"      Morales A, Painter T, Li R, et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation 2010; 121:2176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/35\">",
"      Murali S, Baldisseri MR. Peripartum cardiomyopathy. Crit Care Med 2005; 33:S340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/36\">",
"      Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007; 128:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/37\">",
"      Podewski EK, Hilfiker-Kleiner D, Hilfiker A, et al. Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation 2003; 107:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/38\">",
"      Veille JC. Peripartum cardiomyopathies: a review. Am J Obstet Gynecol 1984; 148:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/39\">",
"      Homans DC. Peripartum cardiomyopathy. N Engl J Med 1985; 312:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/40\">",
"      Mendelson MA, Chandler J. Postpartum cardiomyopathy associated with maternal cocaine abuse. Am J Cardiol 1992; 70:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/41\">",
"      Lampert MB, Hibbard J, Weinert L, et al. Peripartum heart failure associated with prolonged tocolytic therapy. Am J Obstet Gynecol 1993; 168:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/42\">",
"      Kothari SS. Aetiopathogenesis of peripartum cardiomyopathy: prolactin-selenium interaction? Int J Cardiol 1997; 60:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/43\">",
"      C&eacute;nac A, Simonoff M, Moretto P, Djibo A. A low plasma selenium is a risk factor for peripartum cardiomyopathy. A comparative study in Sahelian Africa. Int J Cardiol 1992; 36:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/44\">",
"      Fett JD, Ansari AA, Sundstrom JB, Combs GF. Peripartum cardiomyopathy: a selenium disconnection and an autoimmune connection. Int J Cardiol 2002; 86:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/45\">",
"      Lee W. Clinical management of gravid women with peripartum cardiomyopathy. Obstet Gynecol Clin North Am 1991; 18:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/46\">",
"      Katz R, Karliner JS, Resnik R. Effects of a natural volume overload state (pregnancy) on left ventricular performance in normal human subjects. Circulation 1978; 58:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/47\">",
"      Manolio TA, Baughman KL, Rodeheffer R, et al. Prevalence and etiology of idiopathic dilated cardiomyopathy (summary of a National Heart, Lung, and Blood Institute workshop. Am J Cardiol 1992; 69:1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/48\">",
"      Forster O, Hilfiker-Kleiner D, Ansari AA, et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur J Heart Fail 2008; 10:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/49\">",
"      Fett JD. The role of MRI in peripartum cardiomyopathy. Int J Cardiol 2009; 137:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/50\">",
"      Baruteau AE, Leurent G, Martins RP, et al. Peripartum cardiomyopathy in the era of cardiac magnetic resonance imaging: first results and perspectives. Int J Cardiol 2010; 144:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/51\">",
"      Leurent G, Baruteau AE, Larralde A, et al. Contribution of cardiac MRI in the comprehension of peripartum cardiomyopathy pathogenesis. Int J Cardiol 2009; 132:e91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/52\">",
"      Kawano H, Tsuneto A, Koide Y, et al. Magnetic resonance imaging in a patient with peripartum cardiomyopathy. Intern Med 2008; 47:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/53\">",
"      Caballero-Borrego J, Garc&iacute;a-Pinilla JM, Rueda-Calle E, de Teresa-Galv&aacute;n E. [Evidence of gadolinium late-enhancement on cardiac magnetic resonance imaging in a patient with peripartum cardiomyopathy]. Rev Esp Cardiol 2008; 61:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/54\">",
"      Mouquet F, Lions C, de Groote P, et al. Characterisation of peripartum cardiomyopathy by cardiac magnetic resonance imaging. Eur Radiol 2008; 18:2765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/55\">",
"      Marmursztejn J, Vignaux O, Goffinet F, et al. Delayed-enhanced cardiac magnetic resonance imaging features in peripartum cardiomyopathy. Int J Cardiol 2009; 137:e63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/56\">",
"      Barone-Rochette G, Rodi&egrave;re M, Lantuejoul S. Value of cardiac MRI in peripartum cardiomyopathy. Arch Cardiovasc Dis 2011; 104:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/57\">",
"      Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010; 12:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/58\">",
"      Isezuo SA, Abubakar SA. Epidemiologic profile of peripartum cardiomyopathy in a tertiary care hospital. Ethn Dis 2007; 17:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/59\">",
"      WALSH JJ, BURCH GE, BLACK WC, et al. IDIOPATHIC MYOCARDIOPATHY OF THE PUERPERIUM (POSTPARTAL HEART DISEASE). Circulation 1965; 32:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/60\">",
"      Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995; 333:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/61\">",
"      Bozkurt B, Villaneuva FS, Holubkov R, et al. Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol 1999; 34:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/62\">",
"      Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 2010; 121:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/63\">",
"      Hilfiker-Kleiner D, Meyer GP, Schieffer E, et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol 2007; 50:2354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/64\">",
"      Habedank D, K&uuml;hnle Y, Elgeti T, et al. Recovery from peripartum cardiomyopathy after treatment with bromocriptine. Eur J Heart Fail 2008; 10:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/65\">",
"      Elkayam U, Goland S. Bromocriptine for the treatment of peripartum cardiomyopathy. Circulation 2010; 121:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/66\">",
"      Costanzo-Nordin, MR, O'Connell, JB. Peripartum cardiomyopathy in the 1980's: Etiologic and prognostic considerations and review of the literature. Progr Cardiol 1989; 2:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/67\">",
"      Keogh A, Macdonald P, Spratt P, et al. Outcome in peripartum cardiomyopathy after heart transplantation. J Heart Lung Transplant 1994; 13:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/68\">",
"      Felker GM, Jaeger CJ, Klodas E, et al. Myocarditis and long-term survival in peripartum cardiomyopathy. Am Heart J 2000; 140:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/69\">",
"      Rickenbacher PR, Rizeq MN, Hunt SA, et al. Long-term outcome after heart transplantation for peripartum cardiomyopathy. Am Heart J 1994; 127:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/70\">",
"      Zimmerman H, Bose R, Smith R, Copeland JG. Treatment of peripartum cardiomyopathy with mechanical assist devices and cardiac transplantation. Ann Thorac Surg 2010; 89:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/71\">",
"      Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/72\">",
"      Ravikishore AG, Kaul UA, Sethi KK, Khalilullah M. Peripartum cardiomyopathy: prognostic variables at initial evaluation. Int J Cardiol 1991; 32:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/73\">",
"      Witlin AG, Mabie WC, Sibai BM. Peripartum cardiomyopathy: an ominous diagnosis. Am J Obstet Gynecol 1997; 176:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/74\">",
"      Lampert MB, Weinert L, Hibbard J, et al. Contractile reserve in patients with peripartum cardiomyopathy and recovered left ventricular function. Am J Obstet Gynecol 1997; 176:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/75\">",
"      Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J 2006; 152:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/76\">",
"      Chapa JB, Heiberger HB, Weinert L, et al. Prognostic value of echocardiography in peripartum cardiomyopathy. Obstet Gynecol 2005; 105:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/77\">",
"      Hu CL, Li YB, Zou YG, et al. Troponin T measurement can predict persistent left ventricular dysfunction in peripartum cardiomyopathy. Heart 2007; 93:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/78\">",
"      Dorbala S, Brozena S, Zeb S, et al. Risk stratification of women with peripartum cardiomyopathy at initial presentation: a dobutamine stress echocardiography study. J Am Soc Echocardiogr 2005; 18:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/79\">",
"      Goland S, Bitar F, Modi K, et al. Evaluation of the clinical relevance of baseline left ventricular ejection fraction as a predictor of recovery or persistence of severe dysfunction in women in the United States with peripartum cardiomyopathy. J Card Fail 2011; 17:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/80\">",
"      Goland S, Modi K, Bitar F, et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail 2009; 15:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/81\">",
"      Elkayam U, Tummala PP, Rao K, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med 2001; 344:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/82\">",
"      Sutton MS, Cole P, Plappert M, et al. Effects of subsequent pregnancy on left ventricular function in peripartum cardiomyopathy. Am Heart J 1991; 121:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/83\">",
"      Sliwa K, Forster O, Zhanje F, et al. Outcome of subsequent pregnancy in patients with documented peripartum cardiomyopathy. Am J Cardiol 2004; 93:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/62/18410/abstract/84\">",
"      Fett JD, Christie LG, Murphy JG. Brief communication: Outcomes of subsequent pregnancy after peripartum cardiomyopathy: a case series from Haiti. Ann Intern Med 2006; 145:30.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4945 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-24EF02F2C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_62_18410=[""].join("\n");
var outline_f17_62_18410=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Time of onset",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Inflammatory cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Myocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Abnormal immune response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Familial disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hemodynamic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11716524\">",
"      Role of prolactin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84779155\">",
"      BNP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11716565\">",
"      Cardiac magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Viral and bacterial studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H84779113\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Heart failure treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17112400\">",
"      - Avoid angiotensin inhibition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17112407\">",
"      - Diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17112414\">",
"      - Digoxin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17112421\">",
"      - Vasodilators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17112428\">",
"      - Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17112438\">",
"      - Aldosterone antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17112445\">",
"      - Inotropes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17112452\">",
"      Vasopressors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Arrhythmia management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Immunosuppressive agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Bromocriptine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Heart transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H84779209\">",
"      DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H84779281\">",
"      BREASTFEEDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Maternal outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Obstetric and neonatal outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Subsequent pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Recovered LV function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Persistent LV dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Following heart transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      General issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4945\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4945|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/34/42529\" title=\"diagnostic image 1\">",
"      2D echo of peripartum cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4945|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/48/25358\" title=\"figure 1\">",
"      Etiology cardiomyopathy outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/30/7656\" title=\"figure 2A\">",
"      M-mode echo peripartum CM I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/29/17880\" title=\"figure 2B\">",
"      M-mode echo periparum CM II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4945|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/60/5069\" title=\"table 1\">",
"      Effective dose estimates for imaging tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29097?source=related_link\">",
"      Acquired heart disease and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19465?source=related_link\">",
"      Causes of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34681?source=related_link\">",
"      Critical illness during pregnancy and the peripartum period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=related_link\">",
"      Diagnosis and management of ischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7592?source=related_link\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22986?source=related_link\">",
"      Etiology and pathogenesis of myocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=related_link\">",
"      Indications and contraindications for cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7048?source=related_link\">",
"      Indications for antithrombotic therapy in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7769?source=related_link\">",
"      Inotropic agents in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=related_link\">",
"      Intermediate- and long-term mechanical cardiac support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=related_link\">",
"      Management of heart failure in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/39/10874?source=related_link\">",
"      Natural history and therapy of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12872?source=related_link\">",
"      Nitric oxide, other hormones, cytokines, and chemokines in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20487?source=related_link\">",
"      Pregnancy after cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=related_link\">",
"      Pregnancy in women with congenital heart disease: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/21/35159?source=related_link\">",
"      Pregnancy in women with congenital heart disease: Specific lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14362?source=related_link\">",
"      Supraventricular arrhythmias during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7674?source=related_link\">",
"      Ventricular arrhythmias during pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_62_18411="Agents most commonly ingested by children";
var content_f17_62_18411=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents most commonly ingested by children younger than six years of age from 2006 to 2011",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Cosmetics and personal care products",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cleaning products (household)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Analgesics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foreign bodies/toys/miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topical preparations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cough and cold preparations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antihistamines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pesticides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal preparations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antimicrobials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arts/crafts/office supplies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiovascular drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hormones and hormone antagonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electrolytes and minerals",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Annual Reports of the American Association of Poison Control Centers Toxic Exposure Surveillance System.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_62_18411=[""].join("\n");
var outline_f17_62_18411=null;
var title_f17_62_18412="Infectious diarrhea children";
var content_f17_62_18412=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Infectious causes of acute infectious diarrhea in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Viral",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rotavirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Calicivirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Astrovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Parvovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pestivirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Adenovirus",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Bacterial",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Campylobacter",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Salmonella",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            E. coli",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Shigella",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vibrio cholera",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aeromonas hydrophilia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Yersinia enterocolitica",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Clostridium difficile",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Parasitic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Giardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Entamoeba histolytica",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cryptosporidium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Isospora belli",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Strongyloides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trichuris trichuria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Balantidium coli",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_62_18412=[""].join("\n");
var outline_f17_62_18412=null;
var title_f17_62_18413="OIs HIV endocrine";
var content_f17_62_18413=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Opportunistic infections (OIs) and HIV-associated malignancies reported to affect endocrine glands",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Adrenal",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cytomegalovirus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Cryptococcus neoformans",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Mycobacterium avium intracellulare",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Mycobacterium tuberculosis",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Toxoplasmosis gondii",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Pneumocystis carinii (PCP)",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Histoplasma capsulatum",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Kaposi's sarcoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Lymphoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Gonads",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cytomegalovirus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Toxoplasmosis gondii",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Mycobacterium avium intracellulare",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Kaposi's sarcoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Lymphoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Pancreas",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Mycobacterium tuberculosis",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Mycobacterium avium intracellulare",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Pneumocystis carinii (PCP)",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cytomegalovirus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Toxoplasmosis gondii",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Kaposi's sarcoma",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Parathyroid",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Pneumocystis carinii (PCP)",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cytomegalovirus (CMV)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Pituitary",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cytomegalovirus (CMV)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Pneumocystis carinii (PCP)",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Toxoplasmosis gondii",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Herpetic meningoencephalitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Lymphoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Thyroid",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Pneumocystis carinii (PCP)",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cytomegalovirus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Cryptococcus neoformans",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Aspergillus fumigatus",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Rhodococcus equi",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Haemophilus influenzae",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Microsporidia",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Histoplasma capsulatum",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Paracoccidiodes brasiliensis",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Mycobacterium avium intracellulare",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          <em>",
"           Mycobacterium tuberculosis",
"          </em>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Kaposi's sarcoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Lymphoma",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_62_18413=[""].join("\n");
var outline_f17_62_18413=null;
var title_f17_62_18414="TNM stage append CA";
var content_f17_62_18414=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging of appendiceal carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"5\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"4\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"4\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis",
"      </td>",
"      <td colspan=\"4\">",
"       Carcinoma in situ: intraepithelial or invasion of lamina propria*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td colspan=\"4\">",
"       Tumor invades submucosa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td colspan=\"4\">",
"       Tumor invades muscularis propria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td colspan=\"4\">",
"       Tumor invades through muscularis propria into subserosa or into mesoappendix",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       T4",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"4\">",
"       Tumor penetrates visceral peritoneum, including mucinous peritoneal tumor within the right lower quadrant and/or directly invades other organs or structures&bull;&Delta;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T4a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"4\">",
"       Tumor penetrates visceral peritoneum, including mucinous peritoneal tumor within the right lower quadrant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       T4b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"4\">",
"       Tumor directly invades other organs or structures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"5\">",
"       Regional lymph nodes (N)&loz;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"4\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"4\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"4\">",
"       Metastasis in 1-3 regional lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N2",
"      </td>",
"      <td colspan=\"4\">",
"       Metastasis in four or more regional lymph nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"5\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"4\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       M1",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"4\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       M1a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"4\">",
"       Intraperitoneal metastases beyond the right lower quadrant, including pseudomyxoma peritonei",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       M1b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"4\">",
"       Nonperitoneal metastases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"5\">",
"       <strong>",
"        pTNM pathologic classification",
"       </strong>",
"       . The pT, pN, and pM categories correspond to the T, N, and M categories.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"5\">",
"       <strong>",
"        pN0",
"       </strong>",
"       . Histological examination of a regional lymphadenectomy specimen will ordinarily include 12 or more lymph nodes. If the lymph nodes are negative, but the number ordinarily examined is not met, classify as pN0.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"5\">",
"       Histologic grade (G)&sect;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       GX",
"      </td>",
"      <td colspan=\"2\">",
"       Grade cannot be assessed",
"      </td>",
"      <td colspan=\"2\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       G1",
"      </td>",
"      <td colspan=\"2\">",
"       Well differentiated",
"      </td>",
"      <td colspan=\"2\">",
"       Mucinous low grade",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       G2",
"      </td>",
"      <td colspan=\"2\">",
"       Moderately differentiated",
"      </td>",
"      <td colspan=\"2\">",
"       Mucinous high grade",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       G3",
"      </td>",
"      <td colspan=\"2\">",
"       Poorly differentiated",
"      </td>",
"      <td colspan=\"2\">",
"       Mucinous high grade",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       G4",
"      </td>",
"      <td colspan=\"2\">",
"       Undifferentiated",
"      </td>",
"      <td colspan=\"2\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"5\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage 0",
"      </td>",
"      <td>",
"       Tis",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Stage I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIA",
"      </td>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIB",
"      </td>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIC",
"      </td>",
"      <td>",
"       T4b",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Stage IIIA",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Stage IIIB",
"      </td>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IIIC",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IVA",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M1a",
"      </td>",
"      <td>",
"       G1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       Stage IVB",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M1a",
"      </td>",
"      <td>",
"       G2, 3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M1a",
"      </td>",
"      <td>",
"       Any G",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M1a",
"      </td>",
"      <td>",
"       Any G",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IVC",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1b",
"      </td>",
"      <td>",
"       Any G",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Tis includes cancer cells confined within the glandular basement membrane (intraepithelial) or lamina propria (intramucosal) with no extension through muscularis mucosae into submucosa.",
"     <br>",
"      &bull; Direct invasion in T4 includes invasion of other segments of the colorectum by way of the serosa, eg, invasion of ileum.",
"      <br>",
"       &Delta; Tumor that is adherent to other organs or structures, grossly, is classified cT4b. However, if no tumor is present in the adhesion, microscopically, the classification should be pT1-3 depending on the anatomical depth of wall invasion.",
"       <br>",
"        &loz; A satellite peritumoral nodule or tumor deposit (TD) in the periappendiceal adipose tissue of a primary carcinoma without histologic evidence of residual lymph node in the nodule may represent discontinuous spread (T3), venous invasion with extravascular spread (T3, V1/2), or a totally replaced lymph node (N1/2). Replaced nodes should be counted as positive nodes while discontinuous spread or venous invasion should be counted in the site-specific factor TD.",
"        <br>",
"         &sect; Histologic grading, particularly of mucinous tumors (those with over 50 percent of the tumor consisting of extracellular mucus) is needed to separate stages IVA and IVB.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_62_18414=[""].join("\n");
var outline_f17_62_18414=null;
var title_f17_62_18415="Insertion of Swan Ganz catheter";
var content_f17_62_18415=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary artery catheter insertion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This schematic diagram shows the proper orientation of the pulmonary artery catheter when inserted through the left subclavian vein. The curvature of the catheter is oriented so that it will facilitate passage of the catheter through the cardiac chambers and into the pulmonary artery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_62_18415=[""].join("\n");
var outline_f17_62_18415=null;
